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Glioblastoma multiforme is the most 
devastating form of glial tumors. 
To ensure successful gene therapy 
application in clinics, accurate in 
vivo model is clearly needed. This 
thesis aimed to evaluate the role of 
15-lipoxygenase-1 and macrophages 
in the treatment and pathogenesis 
of malignant glioma and to develop 
rabbit models which would allow for 
tumor debulking surgery. The results 
demonstrated that 15-lipoxygenase-1 
significantly improved animal 
survival. Moreover, rabbit models 
highlighted the possibility for 
surgical debulking procedures 
followed by gene therapy delivery.
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ABSTRACT 
 
Gliomas are the most common primary brain tumors affecting central nervous system. The 
most aggressive and fatal form of glioma is glioblastoma multiforme (GBM). These tumors 
display aggressive behavior by their infiltrative nature and massive formation of tumor 
vasculature which frequently lead to various treatment failures. 
15-Lipoxygenase-1 (15-LO-1) is known to have important roles in inflammation and 
carcinogenesis. Evidence also shows that it carries anti-angionenic properties with 
capability of regressing the activity of angiogenesis in vitro. This study investigated the 
therapeutic roles of 15-LO-1 in malignant glioma as well as interplay of macrophages and 
tumor cells in the tumor microenvironment.  Moreover, the utilization of a larger laboratory 
animal model such as rabbit is nowadays becoming more important as the model enables 
for testing novel treatments and local administration techniques in combination with 
surgery. Therefore, this study also aimed at establishing a resectable rabbit brain tumor 
model via intracranial implantation of VX-2 tumor cells and lentivirus vector mediated 
oncogenic transformation.  
Studies in rat malignant glioma model showed that gene delivery of 15-LO-1 extended 
survival by 18 % which supports the pro-apoptotic role of 15-LO-1 via induction of lipid 
peroxidation in vivo. It also suggested that infiltration of macrophages characterized by M2 
phenotype influenced the promotion of tumor growth in malignant gliomas in vivo and in 
vitro. The refinement of the existing VX-2 rabbit brain tumor model, has made it possible to 
undertake surgical debulking procedures of the tumor which can mimic the clinical reality 
during experimental trials. It was also shown that implantation of rabbit neural stem cells 
which were transduced with AKT, H-Ras and p53 siRNA developed a ganglioglioma 
tumor in rabbit brain.  
In conclusion, this study demonstrated potential role of 15-LO-1 as a new treatment gene 
for the therapy of malignant gliomas. Additionally, this study showed that rabbit brain 
tumor model can serve as a new platform for testing locally delivered promising 
therapeutics in combination with tumor debulking surgery.  
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TIIVISTELMÄ 
 
Glioomat ovat yleisimpiä keskushermoston kasvaimia. Kaikkein aggressiivisin ja tappavin 
muoto on glioblastooma multiforme (GBM). Malignit glioomat pyrkivät levittäytymään 
ympäröivään kudokseen, ja niillä on myös voimakas taipumus muodostaa uusia 
verisuonia. Tämä johtaa usein hoitojen epäonnistumiseen. 
15-lipoksygenaasi-1 (15-LO-1) on tunnettu tärkeästä roolistaan monien syöpien 
tulehduksessa ja karsinogeneesissä. On olemassa näyttöä siitä, että sillä on anti-
angiogeenisiä ominaisuuksia. Tämän tutkimuksen tarkoituksena oli tutkia 15-LO-1:n 
merkitystä pahanlaatuisen aivokasvaimen hoidossa sekä makrofagien ja syöpäsolujen 
vuorovaikutusta tulehduksessa kasvaimen mikroympäristössä. Suuremman koe-
eläinmallin, kuten kanin käyttäminen, on nykyään entistä tärkeämpää, sillä se mahdollistaa 
kirurgian yhdistämisen uusien hoitomuotojen ja paikallisten annostelutekniikoiden 
tutkimiseen. Tämän vuoksi tutkimuksessa pyrittiin kehittämään kirurgisesti operoitava 
kanin aivokasvainmalli käyttämällä kallonsisäisesti istutettuja VX-2 kasvainsoluja ja 
lentivirusvälitteistä geeninsiirtoa. 
Tutkimukset rotan pahanlaatuisessa glioomamallissa osoittivat, että 15-LO-1:n 
geeninsiirto paransi selviytymistä 18 %, mikä tukee 15-LO-1:n lipidiperoksidaatioon 
perustuvaa apoptoottista roolia. Tutkimuksessa todettiin myös, että M2-fenotyypin 
makrofagien infiltraatio kasvaimeen tuki pahanlaatuisten glioomien kasvua sekä 
soluviljelmissä että koe-eläimissä. Kehitettyä kanin VX-2 aivokasvainmallia käyttäen 
onnistuimme menestyksekkäästi käyttämään kasvaimen poistomenetelmiä, jotka 
muistuttavat nykyisiä kliinisiä hoitokäytäntöjä. Osoitimme myös, että kanin aivoihin 
kehittyy gangliogliooma sen jälkeen kun aivoihin on istutettu AKT:lla, H-Ras:lla ja p53 
siRNA:lla käsiteltyjä hermoston kantasoluja. 
Johtopäätöksenä tämä väitöskirjatyö osoittaa, että 15-LO-1 on potentiaalinen, uusi 
hoitogeeni pahanlaatuisten glioomien hoidossa. Lisäksi tutkimuksessa kehitettyä kanin 
aivokasvainmallia voidaan hyödyntää erinomaisesti uusien paikallisesti annosteltavien 
terapeuttisten valmisteiden ja kasvaimen kirurgisen poiston yhdistävissä hoidoissa. 
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1 Introduction 
Gliomas are the most common intracranial tumors in humans; they are responsible 
for serious disabilities and mortalities. Despite intense efforts at finding a novel cure 
or improvements in the existing therapies, the prognosis of patients remains poor, 
with a mean survival of only 14.6 months. These tumors pose many challenging 
problems because of their highly aggressive and locally invasive growth patterns 
which are recognized as the hallmarks of these cancers.  
Recent results have indicated that 15-lipoxygenase-1 (15-LO-1) plays an important 
role in carcinogenesis. 15-LO-1 and its metabolites have anti-cancer properties by 
increasing the rate of apoptosis (Shureiqi et al. 2000)  and inhibiting angiogenesis 
(Harats et al. 2005) in experimental studies. In vivo studies by Viita and her co-
workers revealed anti-angiogenic properties of 15-LO-1 after administration into 
rabbit skeletal muscle. In their study, 15-LO-1 significantly reduced capillary 
perfusion, vascular permeability, vasodilatation, and the capillary number induced 
by VEGF-A and PIGF growth factors (Viita et al. 2008).    
One of the greatest difficulties in tackling malignant gliomas is to have a good 
representation of human glioma behavior in an animal model. This can ensure 
efficient and realistic therapeutic protocols since many promising therapeutics tested 
in animal experiments have failed in clinical trials. In this regards, the requirement 
for a larger animal model seem to be very crucial. A large animal model, such as 
rabbit, offers major advantages as it allows for testing novel treatments and local 
administration techniques in combination with surgery. A similar approach is not 
possible in rodent models with their limited brain sizes.   
The VX-2 brain tumor is an intriguing model which can be utilized as a platform 
for testing novel therapeutics delivery following resection. VX-2 is an anaplastic 
rabbit carcinoma, which once implanted into cortex, grows with several 
characteristics reminiscent of malignant brain tumors. The model is highly 
reproducible and consistently rapid growing in a predictable time.  
The aims of this thesis were to test potential of 15-LO-1 as a new treatment gene 
for the therapy of malignant gliomas as well as to develop new rabbit models to test 
therapeutic efficacy in future clinical trials. Moreover, another aim was characterize 
the BT4C model for studying how macrophages are involved in the development of 
malignant gliomas.   
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3 
 
Literature Review 
2.1 BRAIN TUMORS AND MALIGNANT GLIOMAS 
Brain tumor is one of the most feared disease affecting human beings. It is due to an 
abnormal growth of cancer cells in central nervous system and includes of tumors of 
cranial and paraspinal nerves. The classification of CNS tumors has been established 
by the World Health Organization (WHO) through a resolution of the WHO 
Executive Board and the World Health Assembly since 1979 (Louis et al. 2007).  
 
2.1.1 Epidemiology and tumor incidence  
As one of the most devastating cancers in human, brain tumors are not only difficult 
to treat, but they also cause major mortality among the patients.  Gliomas are the 
most frequent subtype of primary brain tumors which are classified into low grade, 
anaplastic and glioblastoma multiforme (GBM) due to the histopathological 
appearance of the tumors. Malignant glioma (MGs), the most common primary brain 
tumor in adults, is a devastating form of cancer and responsible for a high number of 
mortalities. According to the WHO classification, MGs range from grade III to grade 
IV including Glioblastomas (WHO grade IV), anaplastic astrocytomas (WHO grade 
III), malignant oligodendrogliomas (WHO grade III) and malignant ependymomas 
(WHO grade III) (Louis D.N. et al. 2007). 
 
Table 1: Epidemiology and outcome of malignant gliomas (www.cbtrus.org) (Modified 
from Weller M., 2011) 
 
Glioblastomas account for about 12-15% of all intracranial tumors and 60-75% of 
astrocytic tumors most often affecting adults around the age of 45 and 75 years old. 
Population based-study reported the GBM occurrence to range between 3-4 and 2.96 
new cases every 100 000 population per year in Europe and USA, respectively (Louis 
D.N. et al. 2007). In 2008, a total of 54 805 cases of brain tumors were reported 
throughout Europe, with the incidence found to be more frequent in men. In 
Finland, Finnish Cancer Registry reported 11 new cases for 100 000 population in 
2009 and listed GBM as the 9th most common death in women and 11th in men. 
 
 Incidence for 
100 000 /year 
Survival at 1 
year (%) 
Survival at 3 
years (%) 
Survival at 5 
years (%) 
Anaplastic 
astrocytoma 
0.41 60.3 34.7 27.4 
    49.4 
Anaplastic 
oligodendroglioma 0.12 
79.9 59.6  
     
Glioblastoma 3.19 34.6 7.3 4.8 
4 
 
  
 
 
 
 
 
  
 
 
Figure 1. MRI images from a 61-y old man with a few weeks history of headache and 
confusion. He was otherwise in good condition, walking and talking, slight visual field 
defect on the left side. After the operation, no new deficit was observed but he was 
slightly confused. A and B) Pre operation images: T1 gadolinium enhanced axial images 
showing large necrotic right temporal lobe glioblastoma causing uncal herniation and 
brain stem compression. The tumor is growing over the midline in the region of the 
splenium (B). C and D) Immediate post operation images: T1 gadolinium enhanced axial 
images: The large temporal lobe tumor mass has been resected (C), but the part of the 
tumor growing in right atrium and in the splenium could not be removed (D). Pictures 
were kindly provided by Dr. Arto Immonen MD, PhD; Department of Neurosurgery, 
Kuopio University Hospital. 
 
2.1.2 Clinical and pathological features 
Glioblastomas (GBs) are the most fatal malignant intracranial tumors in adults 
(Huang et al. 2010) and they are featured by intense heterogeneity at various 
histology and molecular levels (Bonavia et al. 2011). A short clinical history of 
patients with primary GBMs is recorded with a duration of less than 3 months in 
more than 50% of cases (Louis D.N. et al. 2007). Secondary GBMs on the other hand 
show slower tumor progression and seems to have originated from low grade or 
anaplastic astrocytomas (Ohgaki, Kleihues 2009). In addition to epileptic seizures 
and personality changes, patients with glioblastomas usually experience headache 
and nausea/vomiting due to the high intracranial pressure (Louis D.N. et al. 2007).  
The tumors often display aggressive behavior by their infiltrative nature and 
extensive formation of tumor vasculature which frequently lead to various treatment 
failures (Tate, Aghi 2009). Other histopathological characterizations typical of GBMs 
include nuclear atypia, cellular pleomorphism, mitotic activity, vascular thrombosis 
and necrosis (Louis D.N. et al. 2007).    
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Figure 2. Histological examination of a glioblastoma multiforme sample. A) Glioblastoma 
multiforme at low magnification (40x). Geographic necrosis, strong endothelial 
proliferation and capillary proliferation are seen. Cellularity is high. B) Glioblastoma 
multiforme at x100 magnification. Geographic necrosis, strong endothelial proliferation 
and capillary proliferation are seen. Cellularity is high, nuclear atypia is clear. C) 
Glioblastoma multiforme at x100 magnification. Initial necrosis and strong endothelial 
proliferation are seen. Cellularity is high, nuclear atypia is clear. Pictures were kindly 
provided by Dr. Jaana Rummukainen MD, PhD; Department of Pathology, Kuopio 
University Hospital. 
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2.1.3 Genetic abberations in glioblastomas  
Various molecular defects have been correlated with an aggressive phenotype of 
GBMs. These include EGFR amplification and overexpression, PTEN loss, AKT 
activation and TP53 mutations.  
About 40% of primary GBMs present with EGFR amplifications contributing to 
60% of protein overexpression. However, similar abnormalities are rarely found in 
secondary GBMs. Deletions have been the most frequent genetic abnormalities 
associated with EGFR amplifications. Most cases show a deletion of exon 2-7 in 
GBMs patients (Ohgaki, Kleihues 2009). EGFR amplifications correlate significantly 
to poor prognosis and a decrease survival of patients with GBMs, particularly 
because EGFR contributes to resistance to radiation therapy and chemotherapy 
(Wang et al. 2011).     
Primary GBMs harbor up to 40% of PTEN mutations while similar abnormalities 
are rarely found in secondary types of GBM (Ohgaki, Kleihues 2009). The loss of 
PTEN has contributed to very low median survival times in GBMs patients as 
compared to patients with high PTEN mRNA. The ability to enhance sensitization of 
glioma cells to chemotherapy and radiotherapy make PTEN as a potential 
prognostic marker (Ware, Berger & Binder 2003). 
A high level of AKT activation is often related to glioma cell migration, cell cycle 
progression and apoptosis inhibition (Wang et al. 2011). Several factors that 
contribute to the high activation of AKT are PTEN loss, through tyrosine kinase 
growth factor receptor, oncogenic RAS and mutation of P13K via P13K/Akt/mTOR 
pathway (Hambardzumyan et al. 2011). 
TP53 is one of the most important gene regulators of cellular function, being 
involved in the cell cycle, response of cells to DNA damage, cell death and cell 
differentiation. In GBMs, TP53 mutations are more commonly found in the 
secondary type than in primary type i.e. incidences of 65% and 28%, respectively 
(Ohgaki, Kleihues 2009).      
2.1.4 Current therapies for brain tumors 
Current treatment options for malignant brain tumors are surgical resection 
followed with radiotherapy and/or chemotherapy. Despite advances in therapeutic 
modalities, the prognosis of the patients remains poor with a mean survival of 14.6 
months after diagnosis (Wirth et al. 2009a) and a 5-year survival rate of only 4.8% 
(Weller 2011). Tumor recurrence has been reported to usually occur within 12-
months after tumor resection. One of the major obstacles to fight over tumor 
recurrence is the highly aggressive and invasive nature of tumors which often lead 
to unsuccessful treatments.  
Resistance of the tumor against surgical procedures is mainly caused by the 
infiltrative characteristics of the aggressive glioma cells which diffuse into the 
surrounding brain tissue (Nikiforova, Hamilton 2011). Currently, the gold standards 
for MG treatment are surgery, combined radiotherapy and chemotherapy. Most 
brain tumors, especially the malignant types, are resistant to traditional 
chemotherapeutic cytotoxic therapies and treatments frequently result in only a 
modest outcome. The protective nature of blood brain barrier (BBB) could be one 
reason for the poor effect, by diminishing the effects of chemotherapeutics and other 
targeted therapies (Sul, Fine 2010).  
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History of therapies for MGs has moderately improved since the 1970s. Surgical 
resection alone has shown to result in median survival of only 3 months, while post-
operative radiotherapy improves the median survival to approximately 8 months 
but no significant improvement was achieved by the introduction of chemotherapy 
agents after surgery (Tran, Rosenthal 2010). Nevertheless, since the alkylating agent 
temozolomide (TMZ) was approved by US Food and Drug Administration (FDA) in 
1999 for treating the recurrent anaplastic astrocytomas, the survival of MG patients 
begins to increase. Concurrent administration of TMZ during radiotherapy followed 
by adjuvant systemic supply after surgery has been shown to be significantly better 
than radiotherapy alone. Median survival of combination chemoradiotherapy 
approach was 14.6 months compared to 12 months from radiotherapy alone (Tran, 
Rosenthal 2010, Clarke, Butowski & Chang 2010).  
2.2 CHARACTERIZATION OF TUMOR SURROUNDINGS 
2.2.1 Cell of origin in glioma formation  
The cancer cell of origin is referred to a small group of cells with high capability to 
promote malignancy. The general concept of cancer stem cells (CSCs) was first 
introduced in 1994 and in 1997 in myeloid leukemia cases (Lapidot et al. 1994, 
Bonnet, Dick 1997) and led to extensive research. There is accumulating evidence to 
support the theory that there is a small population of cells called CSCs or stem-like 
cancer cells which contribute to highly aggressive behavior of cancers (Natsume et 
al. 2011). In gliomas, CSCs was first reported between 2002-2004 (Galli et al. 2004, 
Yuan et al. 2004, Singh et al. 2004, Singh et al. 2003, Ignatova et al. 2002). 
CSCs possess many characteristic similarities as stem cells, with a high capacity 
for DNA repair, resistance to toxic drugs through the expression of several ATP-
binding cassette (ABC) transporters, and a resistance towards apoptosis. In cancers, 
CSCs are frequently associated with ability to self-renew, high adaptation to the 
microenvironment with aberrant differentiation, the ability to promote 
tumorigenesis, enhance migration and regenerate a phenocopy of the original tumor 
when injected in vivo. The unique characteristics of CSCs include the ability to 
differentiate into new type of cells possessing multiple differentiation markers 
(Altaner 2008). 
The involvement of CSCs has also been found in GBMs and it seems to be 
correlated to resistance to therapy. GBMs harbor high degree of cell heterogeneity 
including differentiated and non-differentiated cells. The plasticity of the cells and 
their ability to adapt to the extreme tumor environment allow the cells to survive 
and these characteristics are often linked to the tumor invasion, progression, 
metastasis and drug resistance. There is evidence that CSCs also exist in GBMs; the 
cell population is called glioma-initiating cells (GICs). These cells are characterized 
by their ability to self-renew and confer high resistance to chemotherapy and 
radiotherapy (Natsume et al. 2011).  
In an attempt to determine the ability of GIC to self-renew, glioma cancer cells 
were isolated and cultured in vitro with stimulation of growth factors, basic 
fibroblast growth factor (FGF) and epidermal growth factor (EGF). The cells showed 
a remarkable ability to self-renew and they formed nonadherent neurospheres under 
culture conditions. Staining with specific markers further demonstrated their ability 
for self-renewal i.e. they showed positive staining for nestin and CD133. These are 
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two established markers for undifferentiated neural stem cells (NSCs) and 
hematopoietic stem cells, respectively. Interestingly, those cells are not positive for 
beta-tubulin III and GFAP markers which are markers for differentiated neural 
lineages. In further characterizations, the cells were cultured under optimal 
conditions for differentiation and similar stainings were carried out. It was found 
that the cells started to lose positivity for undifferentiated markers but nevertheless 
exhibited positivity of beta-tubulin and GFAP markers. The findings confirmed that 
the population of cells, which were referred to as GICs, were characterized by high 
plasticity (Singh et al. 2003). The In vivo studies of Bao et al further confirmed the 
involvement of GICs in tumor resistance to radiotherapy. Radiotherapy conducted 
on an in vivo xenograft glioma model evoked an increment in the CD133+ cell 
population by three- to fivefold compared to non-irradiated controls. Their results 
suggested that radiation might be contributing to the development of a more 
aggressive and invasive phenotype of GICs (Bao et al. 2006).    
However, later studies have suggested that CD133 might not be the definitive 
marker for GIC and GIC might not be involved in the initiation of tumorigenesis but 
rather in the later processes of angiogenesis in tumor.  Sakariassen et al and Wang et 
al in their studies have demonstrated that the CD133- cell population, either in 
nonadherent or adherent phenotype, were able to produce tumors in vivo (Wang et 
al. 2008, Sakariassen et al. 2006). This suggested that both CD133+ and CD133- cells 
populations have a high propensity for self-renewal, forming neurospheres and 
induce malignant tumorigenesis (Natsume et al. 2011).  
Currently the most widely used marker to identify GSC is CD133. However, 
many researchers have proved that this is not adequate and additional markers are 
crucially needed. Other markers that have shown potential to be used along with 
CD133 include A2B5, stage-specific embryonic antigen, and aldehyde 
dehydrogenase 1 (ALDH1). Additionally, Sox, Nanog and Oct4, which are the 
embryonic stem cells markers, have shown potential for use as prognostic markers 
for determining the response of GSC to therapy (Binello, Germano 2011). 
The identification of CSCs has led to new perspectives in the development of 
therapies for gliomas. It is believed that CSCs should be one of the main targets in 
attempts to defeat the cancer. New markers able to distinguish between normal stem 
cells and CSCs need to be identified. Therefore, new therapy could be developed 
specifically aiming at the CSCs and/or their microenvironment (Altaner 2008). 
2.2.2 Angiogenesis and vasculogenic mimicry 
Angiogenesis is defined as the process of creating new blood vessels from the 
existing ones. GBM is one of the most angiogenic tumors which has a high 
proliferative capacity and causes endothelial cells hyperplasia. According to the 
histological description of WHO, blood vessels in GBMs are described as having an 
enlarged diameter, high permeability, thickened basement membrane, and highly 
proliferative endothelial cells. High proliferative index shown in GBMs is one of the 
hallmarks for angiogenic switch which is additionally characterized by necrosis, 
break down of existing blood vessels and the extracellular matrix (ECM), and 
eventually new vessel formation. Both hypoxia and genetic alterations are 
collectively involved in turning on the angiogenic switch in GBMs via manipulating 
the secretion of various stimuli from glioma cells, endothelial cells, microglia and 
also ECM (Tate, Aghi 2009).  
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In general, angiogenesis occurs in three consecutive steps. 1) Degradation of the 
existing blood vessels, 2) breaking down the vessel basement membrane and ECM, 
3) migration of the endothelial cells to create new blood vessels (Onishi et al 2011). 
Angiogenesis occurs when pro-angiogenic stimuli provided by the 
microenvironment are sufficient to overcome the anti-angiogenesis stimuli. Hypoxia 
is one of the factors that not only stimulates the process of angiogenesis, but also 
impairs the expression of anti-angiogenic factors in GBMs. Additionally, activation 
of the HIF-1/VEGF-A pathway in GBM also leads to endothelial cell proliferation 
and migration (Tate, Aghi 2009).  
Angiogenesis has been shown to create a favourable microenvironment and 
houses small population of CSCs which are known to have a significant effect on 
tumor resistance to therapy. CSCs are believed to be involved in a process called 
vasculogenic mimicry and are able to create blood vessels without any endothelial 
cells recruitment. Vasculogenic mimicry was discovered in highly aggressive and 
metastatic uveal and cutaneous melanoma (Maniotis et al. 1999). Maniotis and the 
co-workers had found that vasculogenic mimicry developed from the basement 
membrane and aggressive type of the tumor cells lining the vasculature, with genetic 
aberrations without any endothelial cells recruitment. Flow of RBC was detected in 
the vasculature proving that the tubular system had acquired an appropriate shape 
to work as normal blood vessels (Zhang, Zhang & Sun 2007).        
Further research by Hallani et al 2010 discovered the vasculogenic mimicry 
phenomenon in GBM cases. The vessels they found did not stain positive for CD34 
marker, a general marker for endothelial cells. Interestingly, their results suggested 
that vasculogenic mimicry involved GIC which could have rendered the plasticity to 
form the blood vessels without the involvement of any endothelial cells (Weller 2011, 
El Hallani et al. 2010).  
2.2.3 Tumor invasion 
Gliomas are often associated with high invasive capacity which complicates tumor 
targeting. Invasion always occurs at the tumor margin, where even a single cell 
could migrate and invade the healthy brain. Invasion results in the formation of 
many microtumors surrounding the primary tumor.  Many factors are thought to be 
involved in invasion, including the interactions between cancer cells, ECM and 
surrounding cells, and biochemical processes that could promote the invasion 
process (Onishi et al. 2011). 
The aggressive nature of glioma cancer cells along with the abnormal vasculature 
which supports cancer cell survival has been regarded as contributing factors to the 
tumors resistance against therapy. Additionally, the invasion of the tumor cells to 
the healthy brain tissue increases the complexity for any treatment to be curative. 
Therefore, it is important to develop a suitable animal model which could represent 
the aggressive behaviour of angiogenesis and invasion in human (Onishi et al. 2011). 
The currently available models which could mimic closely to human invasive glioma 
cells include: 1) Matrigel invasion chambers (BD Biosciences, Franklin Lakes, NJ) for 
in vitro studies; 2) xenograft models with low serial passaging to maintain 
aggressiveness; 3) implanted glioma stem cells which could show more aggressive 
behaviour, and 4) transgenic mice without certain oncogenes that form spontaneous 
gliomas that can also exhibit a degree of invasiveness (Tate, Aghi 2009).  
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2.3 ANIMAL MODELS TO STUDY MALIGNANT GLIOMAS  
2.3.1 History of animal models for malignant gliomas 
There are various animal models for gliomas which represent excellent tools for 
understanding in vivo mechanisms of MG. Although in vitro experiments are 
important, this kind of approach does not deliver detailed information about the 
aggressive behavior of MGs, such as invasion, angiogenesis and metastasis. Not only 
do they offer opportunities for studying genetic aberrations and the etiology of the 
tumor, but animal models also permits experimental testing of various novel therapy 
regimes for treating MGs. 
Attempts to develop animal model for MGs started in 1951 with 
immunocompetent animals. When investigators tried to implant tumor cells in 
immune-protected areas such as cheek of hamster or anterior chamber of rabbit’s eye 
or in the areas which are partially immunocompetent like the attempt to create 
choriocarcinoma in monkey brain. However, many of the experiments failed and the 
rest had many limitations (Krushelnycky et al. 1991).  
The evaluation of any novel therapy approach, for example gene therapy, requires 
that it can be tested in a good animal model in order to determine the effectiveness 
of the treatment. The faithfulness of genotypes and phenotypes present in the model 
are important factors in the search for therapeutic advances to treat glioma patients 
(Ahmad et al. 2011). There are two main strategies which can be adopted to develop 
animal models for MGs; 1) general methods to induce cancers, such as tumor cell 
implantation and chemical mutagenesis, or 2) targeting specific genes via inducing 
certain genetic mutations (Li et al. 2010).  
2.3.2 General models 
It is well known that chemical mutagen such as DNA alkylating agents like 
nitrosurea derivatives generate point mutations which lead to glioma-like tumor 
formation in the brain (Dai, Holland 2001). Two chemical substances that have been 
widely used for developing MG models in rats are methylnitrosourea (MNU) and N-
ethyl-N-nitrosourea (ENU) (Sughrue et al. 2009). However, these models harbor 
several disadvantages as the tumors usually develop from point mutation/s which 
cannot be identified, therefore they generate non-uniformity among the models. 
Furthermore, it takes a long time to develop a model from this method. 
Cell line models have been demonstrated to provide highly reproducible results 
from implantation of either rodents or human MG cell lines. The tumors grow in a 
predictable period of time and develop tumors at very successful rates (Dai, Holland 
2001). Currently, the existing cell line MG models originate from syngeneic graft of 
rats and mouse and xenograft mouse (Sughrue et al. 2009).  
Xenograft or xenotransplantation is the transplantation of tumor cells from 
different species into immunocompetent animals. The implantation is carried out 
either at the similar original site (orthotopic) or a different site (heterotypic) from the 
donor. In contrast, allotransplantation is transplantation of tumor cells to a similar 
species as the derived tumor cell’s donor. Implantation models, particularly 
xenografts, have provided valuable information in clarifying the biology of MGs. 
However, the model is often criticized for its lack of a functional immune system 
and the fact that human MG cell lines implanted into the brain of the animals do not 
represent the true situation i.e. they do not resemble the formation and progression 
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of human MG since these involve major immune surveillance-escaping mechanisms 
(Hambardzumyan et al. 2011). A comparison of information obtained from high-
density oligonucleotide array based SNPs between MG cell lines and primary 
human MG demonstrated that the MG cell lines harboring similar genetic 
aberrations have several new genetic mutations which are not detected in primary 
human gliomas. Therefore, it was concluded that MG cell lines poorly resemble 
primary human MG though the cell lines do pose some features of MG genotype 
and phenotype (Li et al. 2008).              
2.3.3 Gene specific models 
Major advances in genetic analysis have provided valuable information of how 
diverse genetic alterations correlated with the multistep progression of MGs. This 
opened various possibilities for researchers to develop new animal models via 
alteration of specific genes of interest so that they would have a similar genetic 
resemblance to human MGs. Currently, there are different versions of genetically 
modified animal models for MGs particularly developed in mice (Sughrue et al. 
2009). 
In human MGs, mutational analysis has revealed multiple genetic disruptions in 
signal transduction pathways, cell cycle regulation and apoptosis functions which 
mainly reflect tumor initiation, maintainence and progression (Dai, Holland 2001, 
Fomchenko, Holland 2006). The strategy of modelling animals by adopting certain 
oncogenes, tumor suppressor genes and single genetic mutations have shed light on 
the understanding of molecular pathways in MGs. Transgenic mice may be created 
with oncogenes which allow tissue-specific expression or genetic knockout of certain 
tumor suppressor genes (Hesselager, Holland 2003). 
The fundamental roles of oncogenes and tumor suppressor genes in MGs 
progression are often related to genetic aberrations which cause activation of signal 
transduction pathways and cell cycle arrest pathways (Fomchenko, Holland 2006). 
In order to investigate the causative effect of these genes in glioma initiation and 
progression, one can study these important transduction pathways e.g. the p13 
kinase/AKT pathways, RAS/MAP kinase pathway, C-MYC pathway, protein kinase 
C pathway and STAT pathway. Similarly, deletion of INK4A-ARF, deletion of Rb, 
loss-of-function via mutation of p53, amplification of CDK4, CDK6, cyclin D1 and 
MDM2 are also pathways of major interest (Dai, Holland 2001). 
2.3.4 Rodent models 
The idea to develop a rat brain tumor model started as early as the 1970s. In the 
mouse, one is able to produce genetically modified cell lines and achieved controlled 
tumor growth under optimal conditions. However, the larger size of rat brain (~1200 
mg) compared to the mouse (400 mg) offers more advantages for more accurate 
tumor cell implantation in larger volumes.  
This study utilized the BDIX rat MG model which was developed from 
implantation of BT4C rat MG cell line.  
2.3.4.1 BT4C rat model 
The BT4C rat MG model was developed from a single transplacental administration 
of N-ethyl-N-nitrosourea (ENU) to a pregnant BDIX rat. The tumor was isolated and 
cultured for 200 days to allow it to become tumorigenic. The tumor cells were then 
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implanted into another BDIX rat’s brain and pathological examination demonstrated 
its tumor characteristics such as multipolar glia-like cells and flattened cells with 
fewer and shorter cytoplasmic processes and occasional giant cells. Inoculation of 
BT4C cells into BDIX rats does not induce immunologic reactions in the animals 
which makes it suitable for in vivo testing. The BT4C model has been widely used for 
evaluating novel chemotherapeutic agents, antitumor effects of gene therapy and 
angiogenic therapies, alone and in combination with radiation and TMZ. 
Furthermore, this model is suitable for studying the molecular and biological effects 
of chemotherapy, radiotherapy and suicide gene therapy (Barth, Kaur 2009). 
Despite the fact that rodent models have been poorly characterized from the 
histopathological point of view, this model has proven to be very useful in 
preclinical testing including suicide gene therapy (Sandmair et al. 1999), anti-
angiogenic agents (Huszthy et al. 2006), chemotherapeutic targeting strategies 
(Wibom et al. 2010). It has been widely used in testing novel therapies for gliomas, 
especially those targeting angiogenesis and invasion. The tumors in rodent model 
are also fast growing, highly reproducible and it is possible to have good control 
over the site of the tumor growth.    
2.3.5 Large animal models 
However, translation of successful findings in rodent models has been difficult due 
to the lack of a larger animal model which could better mimic human MG. Many 
studies have stated the advantages of using larger animal models including dogs 
and cats (Krushelnycky et al. 1991, Candolfi et al. 2007). 
The dog is a rather good alternative as a large animal model i.e. large size of brain 
and the spontaneous glioma occurrence resembles closely human MGs. Dogs and 
humans also share similarities in MRI neuroimaging features making dog models 
useful for preclinical assessment of novel therapies. However, since dogs are pets, 
recruitment of dogs spontaneous MGs for testing novel drugs might prove difficult 
as compared to rodent models. Furthermore, the cost for housing dogs is much 
higher than with other models (Candolfi et al. 2007). 
In this study, we utilized the rabbit VX-2 brain tumor model for testing novel 
therapy delivery following tumor resection. VX-2 is an anaplastic rabbit carcinoma, 
which once implanted into cortex grows with several of the characteristics of 
malignant brain tumors. The tumor cells arose from a virus-papilloma in a domestic 
rabbit in 1930 (Carson, Anderson & Grossman 1982). Serial transplantation of the 
tumor cells induced more aggressive behavior and the tumor became anaplastic after 
several passages. The VX-2 tumor has also shown a metastatic capability mostly to 
organs like lymph nodes and lungs (van Es et al. 2000). 
Interestingly, VX-2 tumor can be easily passaged in the thigh of the rabbit. 
Optimal size can be reached at 2 weeks of implantation and tumor can be harvested, 
dissociated and resuspended for further inoculation. The VX-2 brain tumor model 
yields a consistent, fast growing tumor with high reproducibility in rabbit brain. The 
animals survive between 10-18 days after intracranial tumor implantation. 
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Table 2. Summary of strategies used to generate experimental malignant glioma models 
in animals. 
 Advantages Disadvantages 
1. Not gene specific   
     a.Mutagens Resemble human brain 
tumor in animals where 
tumor growth occurs non-
spontaneously 
Unknown mutations which 
may generate non-
uniformity among animal 
models 
Takes long time to develop 
 
     b.Transplantation  
     (xeno-  or allografts) 
Highly reproducible Small sizes of available rat 
and mouse models so far 
limit the possibility of tumor 
resection 
 
 Tumor grow in predicted 
time 
Unknown mutations 
2. Gene specific   
     Genetic modification Known mutations Unknown cells of origin 
 Tumor growth occurs non-
spontaneously 
 
 
2.3.6 Implications for preclinical testing  
Gene therapy, oncolytic virotherapy and immunotherapy are examples of promising 
therapeutic strategies against brain malignancies. However, studies in rodent 
models have shown that the local administration route is superior for optimal 
efficiency and safety with these therapy modalities. The lack of an easily available 
resectable brain tumor model may be one of the reasons why these promising 
therapy modalities have often failed to be translated from rodent models to human 
patients, as the preclinical and clinical treatment strategies vary extensively. The 
efficient evaluation of novel therapies requires reproducible and accurate animal 
models that not only capture key features of the disease but are also able to 
reproduce the treatment regimes actually used in the clinical environment, 
particularly surgical debulking which is known to be a critical intervention. Thus, 
the rodent models widely utilized in basic research are unable to predict the effects 
of resection on the course of therapy. Surgical intervention not only affects the 
application route of further treatments, but it is believed that it may change the 
efficacy of adjuvant therapies (Ng, Wan & Too 2007, Stewart 2002, Barker et al. 2001). 
Importantly, after debulking of the aggressive primary or metastatic brain tumor, 
invasive cells will frequently give rise to a recurrent tumor, which grows adjacent to 
the resection margin and leads to a fatal outcome. After resection of VX-2 tumors, 
the cavity walls are characterized by malignant cells intermingled with the brain 
parenchyma as is the case in patients after surgery. For example local delivery of 
gene therapy vectors into the wound bed enables an evaluation of the safety and 
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efficacy in an environment where most of the surrounding cells are normal brain 
cells mixed with a relatively small proportion of malignant cells. This may provide 
important information if the treatment effect is thought to be extended from the 
primary target cell to neighboring malignant cells as in cytotoxic or anti-angiogenic 
therapy or immunostimulatory gene therapy with cytokine genes.  
The size of tumors and brains of routinely used rodent models in comparison to 
humans varies by several orders of magnitude which complicate their use in 
predicting adequate drug concentrations and further resection is particularly 
challenging, even impossible. Canine brain tumors are characterized with features 
similar to those in encountered in human patients and the animal’s relatively large 
brain size allows for assessment of doses and the volumes needed to achieve 
therapeutic effects (Candolfi et al. 2007). Therefore, dogs can serve as a valuable 
model for testing of novel treatment regimes. However, the supply of sufficient 
research cohorts from veterinary clinics is complicated due to the low incidence of 
canine brain tumors. Thus the rabbit VX-2 brain tumor model mimics closely the 
clinical scenario, where new therapies are applied after surgical resection and it can 
serve as a reproducible laboratory animal model.  
2.4 GENE THERAPY FOR MALIGNANT GLIOMAS 
2.4.1 The history of gene therapy 
Gene therapy is generally defined as a therapeutic approach for correcting defective 
genes by delivering genetic materials into cells. The use of a viral vector as the main 
delivery mechanism is known as viral gene therapy. At present, the most widely 
studied gene therapies involve cancers and hereditary diseases and several different 
approaches have been used in their therapy. The optimal scenario for gene therapy is 
to obtain an optimal response specifically in the target area achieving a favorable 
outcome with the least possible side effects elsewhere. 
Gliomas are the perfect target for gene therapy because of their dismal prognosis, 
localized growth in restricted brain areas and the absence of metastasis. In 1992, the 
first clinical trial for brain tumors was published by Brenner et al; these workers 
studied the delivery mechanism of the IL-2 gene using retroviral vectors in to 
neuroblastoma patients. Subsequently, several researchers had initiated other 
clinical trials using the HSV-tk suicide gene therapy approach with intravenous 
Ganciclovir (GCV) (Oldfield et al. 1993, Ram et al. 1993, Immonen et al. 2004, 
Sandmair et al. 2000). Currently the most widely utilized gene therapy approaches 
for brain tumors are suicide gene therapy, cytokine gene therapy, oncolytic 
virotherapy and immune gene therapy mainly involving herpes simplex virus and 
adenoviruses. MGs are the most extensively targeted group of brain tumor gene 
therapy. The two mainly registered clinical trials for brain tumors are cytotoxic gene 
therapy and suicide gene therapy methods with a total numbers of 34 and 32 
respectively (Maatta et al. 2009). Currently, a total number of 1786 gene therapy 
clinical trials have been registered. These include 1076 trials in phase I, 333 in phase 
I/II, 294 in phase II, 16 in phase II/III, 63 in phase III and 2 in phase IV. 
(http://www.wiley.com//legacy/wileychi/genemed/clinical/). 
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2.4.2 Gene delivery  
Gene delivery can be achieved either by a physical approach such as electroporation, 
ultrasound and gene gun or via viral and non-viral vectors. Non-viral vectors for 
gliomas include synthetic liposomes or nanoparticles (Wirth et al. 2009a). However, 
currently, viral vectors are the most important vehicles in gene therapy due to their 
efficiency and specificity at infecting host cells and expressing the transgenes 
(Chiocca, Aghi & Fulci 2003). Adenoviruses are one of the most widely used viral 
vectors in gene therapies clinical trials (http://www.wiley.co.uk/genmed/clinical/). 
Additionally, oncolytic viruses such as HSV-1, Measles, Newcastle Disease Virus 
(NDV), Reovirus, Poliovirus and Vesicular Stomatitis Virus (VSV) have also been 
tested (Aghi, Chiocca 2006). 
Some viruses are obligate intra-cellular parasites with the ability to infect cells and 
insert their DNA into host genome which is eventually transcribed during viral 
replication. In gene therapy approaches, virus replication is usually blocked by 
removing those sequences necessary for replication and replacing them with the 
therapeutic gene of interest. The importance of this modification is two fold: to 
assure the production of the therapeutic genes and for safety reasons (Kanzawa et al. 
2003). 
Delivery mechanism of genetic materials to the patients can be achieved either by 
direct delivery to the cells (in vivo) or by altering the genes of cells outside of the 
human body and transferring them back to the patients (ex vivo). Glioblastoma was 
the first reported cancer for which the in vivo technique was used for gene delivery 
(Engelhard 2000). 
2.4.2.1 Retrovirus (Rv) and lentivirus 
Retroviruses belong to the family of Retroviridae which are RNA-based viruses. Rv is 
highly capable of infecting dividing host cells and converting its RNA to DNA via 
reverse transcriptase activity. The DNA formed is subsequently inserted into the 
host genome before being transcribed and translated into protein (Anson 2004). 
Retroviral vectors are mostly based upon the Moloney murine leukaemia virus (Mo-
MLV), which is an amphotrophic virus capable of infecting both mouse cells and 
human cells thus enabling vector development in mouse models and subsequently 
on to human treatment. The Rv genome is relatively small (between 8-11 kb) and 
easy to manipulate which makes it suitable for viral vector production (Romano et 
al. 2000). In viral vector development, the genome of Rv is modified by replacing the 
genes encoding for gag(capsid), pol(reverse transcriptase) and env(envelope 
glycoprotein) with specific transgene of interest (Tyynelä K. 2006). 
In terms of MG therapy, Rv has advantages as a viral vector because of its natural 
activity to infect dividing cells and not the non-dividing neurons. Therefore, the 
postmitotic non-dividing brain tissue is left unaffected. Rv has also shown stable 
integration of the transgene and it achieves long term expression of the target 
proteins. Additionally, Rv has been shown to be safe with minimal risk of toxicity 
associated with intracranial application (Aghi, Chiocca 2006). However, the titers of 
the Rv packaging cells production are relatively low and its small size genome limits 
transgene insertion into the cassette. Due to the fact that Rv can integrate into 
dividing cells, there is a high risk of insertional mutagenesis and oncogene activation 
which may eventually lead to cancer development (Kanzawa et al. 2003).  
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Lentiviruses (LVs) belong to a subclass of Rv. LVs are considerably more complex 
than Rv with additional six proteins, tat, rev, vpr, vpu, nef and vif. It has been shown 
that LV can infect both dividing and non-dividing cells in a broad range of tissues, 
be stably integrated into the host genome and produce long term gene expression in 
brain, liver, muscles and retina (Miyoshi et al. 1998). 
2.4.2.2 Adenovirus  
Adenoviruses (Ad) were first isolated from adenoid tissues in 1953 and currently 
there are recognized as being more than 50 serotypes (Russell 2009, Volpers, 
Kochanek 2004). Adenovirus infection is often responsible for respiratory system 
illnesses including acute respiratory infections, pharyngitis and conjunctivitis, 
epidemic keratoconjunctivitis, gastroenteritis and pneumonia in young children. 
Ad is a non-enveloped, icosahedral virus with 60-90 nm in diameter. It possesses 
linear double stranded DNA and has a genome size of 30-40 kb (Volpers & 
Kochanek, 2004). Ads are composed of an icosahedral capsid consisting of three 
major proteins, hexon (II), penton base (III) and knobbed fibre (IV) with some other 
minor proteins which gives Ad a molecular weight of about 150 MDa (Russell 2009, 
Volpers, Kochanek 2004). The Ad genome is capable of accommodating up to a 10 kb 
transgene, conferring advantages in terms of gene therapy (King et al. 2008, Lam, 
Breakefield 2001a).  
Ad is the most extensively used viral vector in gene therapy clinical trials 
(Immonen et al. 2004, Sandmair et al. 2000), especially serotypes Ad2 and Ad5 which 
have been designed as replication defective viruses being generally used in gene 
therapy (Engelhard 2000). Therapeutic genes are designed to be inserted into regions 
of E1A and /or E1B genes, and E2 and E4 genes replacing the original virus 
sequences (Lam, Breakefield 2001a). However, some drawbacks have been reported 
from the generation of these kinds of viruses including, 1) maintenance of the viral 
genome is rapidly lost in dividing cells, 2) viral tumorigenicity, and 3) receptor-
mediated uptake of the virus through the primary Ad receptor, CAR, whose 
expression inversely correlates with malignancy (Aghi, Chiocca 2006).     
Ad is capable of infecting various types of quiescent and proliferating cells 
including lung, skeletal muscles, heart, liver, blood cells and the central nervous 
system. In gene therapy approaches, gene expression from Ad viral vectors occurs 
without integration of the virus into host genome (Kanzawa et al. 2003). Additional 
advantages of Ad viral vectors are the ability to be produced in high titers (1012-1013 
viral particles per ml) and the low pathogenicity of the virus. However, Ad viral 
products have been reported to carry high antigenicity and have been associated 
with toxic and inflammatory responses in the brain. Additionally, the cytotoxic 
(CTL)-mediated immune response often leads to clearance of vector transduced cells 
and to a short duration of transgene expression (Volpers, Kochanek 2004, Lam, 
Breakefield 2001b).  
2.4.2.3 Other viral vectors  
HSV is a DNA virus and it has several major advantages with respect to gene 
therapy. HSV is a common human pathogen which can be found in most people and 
it can infect both proliferating and non-proliferating cells (Lam, Breakefield 2001a). 
In addition to the ability to replicate in neuronal cells and kill brain tumor cells, HSV 
has been shown to cause fatal encephalitis in humans (Biederer et al. 2002).  
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HSV has several advantages including high titers of production (108 to 1010 
pfu/ml), ability to house a huge size of a transgene (up to 30 kb in size) without 
affecting the titers or replication, effective delivery system in CNS due to 
neurotropism, sensitive to antiherpetic agents like ganciclovir and low risk of 
integration into the host genome, thus reducing the risk of insertional mutagenesis. 
However, due to its very large viral genome size, the manipulation of the virus 
becomes more complicated in vitro. Additionally, many people have been found to 
posses preexisting HSV in their body thus providing immunity that could lead to 
gene delivery failure (Aghi, Chiocca 2006, Romano et al. 2000). Two types of HSV 
that have been used in clinical trials of glioma gene therapy are HSV-G207 and HSV-
1716. The two types of viruses are conditionally replicating HSVs with specific gene 
mutations and a selective ability to replicate only within dividing cancer cells, 
leading to oncolysis (Samaranayake 2007). 
Another type of virus that has shown promising results in glioma gene therapy is 
adeno-associated virus (AAV) which is a native human parvovirus. This virus enters 
into the host cells by binding to heparin sulfate and is able to replicate via the 
assistance of adenovirus or herpes virus. Normally, infection of AAV does not cause 
any disease in humans though integration of the virus genome into host genome 
does occur. The fact that AAV requires help from either adenovirus or herpes virus 
for its replication, is a clear drawback with this virus in the gene therapy approach. 
Additionally, the possible transgene that can be inserted into AAV genome is quite 
small (5 kbp only) and gene expression may not be so efficient (Kanzawa et al. 2003).   
Other viruses that have been studied in gene therapy for gliomas include 
Newcastle Disease Virus (NDV), Poliovirus, Measles and Vesicular Stomatitis Virus. 
NDV is an enveloped negative-stranded oncolytic RNA virus (Aghi, Chiocca 2006) 
with the ability to induce necrosis in cancer tissue. Secretion of different cytokines 
such as interferon and IL-1 may provide an anti-tumor effect in gene therapy 
procedures (Biederer et al. 2002). 
Poliovirus is a RNA virus which can specifically infect and replicate in tumor cells 
due to the tumor-specific expression of human poliovirus receptor CD 155. 
Poliovirus does not integrate and replicate in postmitotic cells like neurons and has 
been shown to be nonpathogenic in primates. In one study, intracranial injection of 
the poliovirus resulted in 80% long-term survival at 50 days in immunodeficient 
mice (Aghi, Chiocca 2006).  
2.4.3 Gene therapy strategies for glioblastoma multiforme 
Gene therapy undoubtedly holds great promise for treating various types of cancers 
including GBM. However, it does seem likely that no single therapy will be 
sufficient to eradicate the tumor completely. Therefore, the combination of 
conventional treatments with novel gene therapy modalities seems to be the 
preferred choice. There is such a remarkable potential in the rapidly growing gene 
therapy field for GBM, however, one has to admit that it has not yet been proven to 
be a success story. Thus numerous experimental trials on animal models that 
pointed to great promise for GBM treatment (Sandmair et al. 1999, Germano, Binello 
2009). But nevertheless, in clinical practice there are substantial obstacles to 
overcome.  
Currently, only a few protocols have been adopted for human studies with 
varying results. Until now, more than 1700 gene therapy clinical trials were 
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registered at journal of Gene Medicine website 
(www.wiley.co.uk/genetherapy/clinical) with more than 60% of the trials were 
cancer related. About 64% of the trials were conducted in United States, 29% in 
Europe with 0.3% in Finland. The rate limiting steps for successful gene therapy for 
brain tumors lie in the efficiency and safety of viral vectors. However, it is believed 
that the greatest shortcoming originates from the lack of efficiency that is partly 
caused by the treatment limitations and delivery methods.  
There are four important gene therapy approaches for gliomas: 1) pro-drug 
activation/suicide gene therapy; 2) transfer of tumor suppressor genes and cell cycle 
modulators;  3) genetic immune modulation; and 4) anti-angiogenic therapy. 
2.4.3.1 Pro-drug activation/suicide gene therapy 
Pro-drug activation, which is also known as suicide gene therapy, refers to the 
concept of delivering genetic material encoding for certain enzymes which are able 
of metabolizing non-toxic drugs into toxic agents (via the suicide gene) which 
subsequently kill the tumor cells.  
2.4.3.1.1 Herpes Simplex Virus type 1/thymidine kinase-Ganciclovir (HSV-
tk/GCV)   
HSV-tk/GCV is the most commonly used gene therapy approach for GBM. In this 
two-step therapy approach, the HSV-tk enzyme converts the non-toxic nucleoside 
analog, GCV into phosphorylated compounds which kill actively dividing cells, 
particularly tumor cells (Aghi, Chiocca 2006, Wirth et al. 2009b). GCV is a synthetic 
acyclic analogue of 2’-deoxy-guanosine, chemically denoted as 9-[[2-hydroxy-1-
(hydroxymethyl)ethoxy]methyl]guanine. In the pro-drug activation approach, HSV-
tk has a higher capability compared to any other mammalian enzymes to 
phosphorylating GCV and subsequently changes its conformation into the GCV-
monophosphate residue (Maatta et al. 2009, Wirth et al. 2009b). Further 
phosphorylations by intracellular kinases converts GCV-monophosphate into GCV-
triphosphate (GCV-TP) which is able to inhibit DNA polymerase or it can be 
incorporated into DNA, resulting to DNA chain termination. This mechanism of 
action specifically targeting DNA replication particularly in S-phase, confers the 
advantage that only dividing tumor cells will be affected (Wirth et al. 2009a). 
The efficiency of this approach depends very much on the bystander effects of 
the enzyme activities. This refers to the killing of cells adjacent to those cells being 
transduced with HSV-TK/GCV. These cells do not express the enzyme but suffer 
similar effects through cell-to-cell contact via gap junctions which allow for the 
transfer of GCV triphosphate from HSV-TK+ cells to non-transduced cells. The 
activation of the enzyme in the transduced and adjacent cells promotes the 
formation of the cytotoxic molecules which contribute to the increment of the 
treatment efficiency and cell death (Sandmair et al. 2000, Aghi, Chiocca 2006, 
Kanzawa et al. 2003). 
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Figure 3. Schematic representation of therapy with Herpes simplex virus-thymidine 
kinase gene/ganciclovir genes in tumor cells. In this approach, HSV-tk is administered 
via gene transfer followed by introduction of non-toxic pro-drug GCV. The pro-drug 
activating enzyme HSV-tk converts non-toxic pro-drug GCV into GCV-monophosphate. 
The cell’s own enzymes additionally phosphorylate GCV-monophosphate into GCV-
biphosphate and GCV-triphosphate which are ultimately the toxic metabolites. GCV-
triphosphate is a nucleotide analogue which is able to be incorporated into DNA and to 
inhibit DNA replication, thereby causing apoptosis.   
Gene therapy via the HSV-tk approach has been evaluated in clinical trials (phase 
III) in many countries using retrovirus and most recently adenovirus (Asadi-
Moghaddam, Chiocca 2009, van Putten et al. 2010).  Until September 2008, a total of 
34 clinical trials had been registered worldwide, with MG the biggest sub-group 
being treated. HSV-tk has been the most widely used approach being examined in 32 
clinical trials (Maatta et al. 2009).  
2.4.3.1.2 Cytosine Deaminase /5- Fluoro Cytosine (CD/5-FC) combination  
5-Fluoro Cytosine (5-FC) is an anti-fungal agent that is generally used to treat fungal 
infections (Asadi-Moghaddam, Chiocca 2009). In the gene therapy modality, this 
prodrug is converted into the active and toxic form of 5-fluorouracil (5-FU) by an 
enzyme called cytosine deaminase (CD). The toxic effects of 5-FU are mediated by its 
intracellular metabolites, i.e. conversion of 5-FU onto 5-fluoro-2’-deoxyuridine-5’-
monophosphate which causes DNA strand breakage leading to cell death (Aghi, 
Chiocca 2006).  
It has been shown that tumor cells receiving CD may synthesize CD peptides of 
the MHC Class I which could lead to immune activation. The CD/5-FU combination 
renders a strong bystander effect compared to HSV-tk due to its ability to enter 
nontransduced cells (Lam, Breakefield 2001a). Adenovirus has been used in the 
experimental studies for CD/5-FU combination. There is only one registered study 
which is now at the stage of recruiting patients for a Phase I clinical trial 
(http://clinicaltrials.gov).  
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2.4.3.1.3 Cyclophosphamide (CPA) 
Another pro-drug activating enzyme that has been well-characterized in gene 
therapy is rat cytochrome P450 2B1/cyclophosphamide (CPA). CPA is a pro-drug 
agent activated by a liver-specific enzyme of the cytochrome P450 family into the 
cytotoxic phosphoramide mustard (PM). PM is produced in a stable and diffusible 
form with an ability to enter adjacent cells i.e. it does not need contact-dependent 
properties to exert bystander effects (Aghi, Chiocca 2006).  
This approach has initially been developed for the use in brain tumors (Chen, Yu 
& Waxman 1997). Studies using RV have shown great promise at reducing MG 
progression in mice (Manome et al. 1996, Wei et al. 1995). Additionally, 
manipulation of replication-conditional HSV vector has been used for achieving 
P450 2B1/CPA in MG treatment (Aghi et al. 1999). Manipulated HSV-1 virus 
carrying the P450 gene acts via 3 modes; 1) evoking viral oncolysis; 2) exposing the 
infected cells to CPA; 3) rendering the infected cells sensitive to GCV (Asadi-
Moghaddam, Chiocca 2009). 
In addition to its ability to diffuse through membranes and act on neighboring 
cells, use of cytochrome P450 is also less immunogenic than other suicide gene 
therapy approaches, such as HSV-tk, thus providing long term drug activation 
(Karle et al. 2001). However, due to the fact that cyclophosphamide’s active 
metabolites can only be generated by liver P450 and these metabolites are poorly 
transported across the BBB, the efficiency in treating glioma may be limited (Aghi, 
Chiocca 2006). 
2.4.3.2 Transfer of p53 tumor suppressor genes  
Various studies have shown that alterations of different oncogenes and tumor 
suppressor genes controlling the cell cycle are involved in GBM progression. These 
alterations may cause disruptions of normal functions of the cells and lead to the 
uncontrolled proliferation of cancer cells. The mechanisms by which cells lose the 
normal functions of the tumor suppressor genes include loss of heterozygosity, 
methylation, cytogenetic aberrations, genetic mutations, gain of autoinhibitory 
function and polymorphism (Garrett 2001).  
p53 tumor suppressor gene is generally inactivated in 35-60% of human MGs. Pre-
clinical trials with adenovirus mediated p53 gene transfer have achieved promising 
results with growth inhibition of transplanted GBM and prolongation of the survival 
of the animals. Their phase I clinical trial (Lang et al. 2003) also reported median 
survival of the GBM patients was 10 months and no-recurrence has been reported in 
one patient for up to 3 years.  
There are also reports indicating that p53 gene transfer is not as effective as wild 
type p53 and GBM is a mixture of cells with mutated p53 and wild-type p53 which 
resulted in only partially effective p53 gene therapy. Subsequently, p53 gene therapy 
combinations have been introduced in order to increase the therapeutic effect. For 
example, p53 in combination with radiation has been reported to improve the 
positive effects in heterogenous cells. One interesting study by Huang et al showed 
that combination therapy of p53 with HSV-tk/GCV suicide gene therapy achieved a 
synergistic effect in C6 rat glioma model (Huang et al. 2007). Furthermore, p53 in 
combination with oncolytic virotherapy has improved the survival in animal models 
(Geoerger et al. 2004). 
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2.4.3.3 Immune gene therapy  
The concept of immune gene modulation in cancers refers to the use of various 
cytokines to enhance the immune response against tumor cells. The most widely 
studied cytokines in MGs have been interleukin (IL)-2, IL-4, IL-12, interferon (IFN)-
β, IFN-γ, 39 and granulocyte-macrophage colony stimulating factor (GM-CSF) 
(Kanzawa et al. 2003, Lam, Breakefield 2001a).  
MG is an attractive target for immune gene therapy because it is located within 
the BBB and it does not have any drainage system. Immune gene therapy can be 
achieved either via active or passive strategies. Active immunotherapy provides 
long-term immunity via up-regulating the immune response. On the other hand, 
passive immunotherapy refers to the delivery of immune effectors to achieve an 
immediate effect but for only a short time. Various studies are currently ongoing for 
both active and passive immune gene therapy for GBM (Clarke, Butowski & Chang 
2010). 
Inductions of cytokines production in GBM are achieved either by direct cell 
transplants or through delivery of a genetically engineered virus which carries 
specific transgenes. One of the promising immune gene therapy approaches is using 
EGFRvIII as a tumor specific antigen to induce the immune system to attack the 
tumor cells. This study has entered phase 2/3 clinical trials with promising results 
(Yamanaka 2008).  
Another cytokine that has shown efficacy in experimental animals is IFN- α. The 
cytokine, IFN- α, inhibits cell cycle progression and induces apoptosis in tumor cells 
thereby leading to an enhanced immune system reaction by increasing the 
expression of MHC-1. IFN- α has been shown to be able to reduce the size of a 
glioma in animal model when co-delivered with DCs into the tumor (Tsugawa et al. 
2004). 
2.4.3.4 Anti-angiogenic therapy 
One of the promising areas to improve the efficiency of the gene therapy in GBMs is 
by targeting angiogenesis. There is increasing evidence that MGs require a rich 
blood supply to sustain their growth and glioblastomas have been shown to be the 
most densely vascularized human tumors (Kunkel et al. 2001). In 1971, the idea of 
inhibition of angiogenesis first appeared and triggered extensive research in the 
field. Important regulators of angiogenesis have been identified and isolated, and 
today some of those represent therapeutic targets.  
Angiostatin, an internal peptide fragment of plasminogen, has recently been 
shown to potently inhibit endothelial proliferation in vitro and to slow down tumor 
growth in vivo. Animal experiments have demonstrated a decrease in tumor volume, 
a decrease of tumor vascularity but an increase in tumor cell apoptosis in the nude 
mouse model transduced with adenovirus expressing angiostatin. Recombinant 
angiostatin could inhibit growth and the neovascularization of intracerebral glioma 
xenografts, as well as to being able to increase tumor cell apoptosis (Rege, Fears & 
Gladson 2005).  
Endostatin, a 20-kDa carboxyl-terminal proteolytic cleavage fragment of collagen 
18 is also a potential angiogenic inhibitor. Endostatin was originally reported to 
inhibit the proliferation of bovine capillary endothelial cells, but not the proliferation 
of cells of non-endothelial origin, and also to inhibit angiogenesis in the chick 
chorioallantoic membrane model. However, complete tumor inhibition was not 
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observed in either the athymic or immunocompetent animal glioma models 
(Kanzawa et al. 2003, Rege, Fears & Gladson 2005).  
Despite some failures, there is still much research into finding new anti-
angiogenic therapies for gliomas. Some researchers have shown interest in the 
potential of bevacizumab (avastin) shown in non-small-cell-lung cancer, renal cell 
cancer and metastatic breast cancer. Bevacizumab is anti-VEGF-A monoclonal 
antibody which has been approved by the FDA for the treatment of metastatic 
colorectal cancer in combination with 5-fluorouracil (FU)-based chemotherapy 
regimens. Clinical trials of bevacizumab in MG patients have been carried out by 
some researchers but no conclusive data has been published as yet (Vredenburgh et 
al. 2007).  
 
2.4.4 15-Lipoxygenases in malignant tumors 
2.4.4.1 Introduction to 15-Lipoxygenases and its family 
Lipoxygenases (LOs) belong to the family of oxygenases and act as lipid-
peroxidizing enzymes to oxygenate unsaturated fatty acids including arachidonic 
acid (AA) in the presence of lipid sources and atmospheric oxygen (Kuhn, O'Donnell 
2006). The oxygenation produces a wide variety of metabolites which are involved in 
many pathophysiological conditions. Most human LOs are encoded by genes which 
are located in the chromosome 17p region (Kelavkar, Glasgow & Eling 2002). 
Lipoxygenases metabolize AA into the biologically active eicosanoids and various 
lipid products which are able to take part in cellular proliferation, apoptosis, 
differentiation and senescence (Pidgeon et al. 2007).   
LOs are expressed in human cells and are present in three subtypes: 5-LO, 12-LO 
and 15-LO. The names are given due to the ability of the enzyme to catalyze the 
insertion of molecular oxygen into AA at carbons 5-, 12- and 15- respectively. 5-LO is 
involved in synthesis of leukotriene (LT) from AA into LTA4. Further enzymatic 
reaction via hydrolysis and conjugation with glutathione cnverts LTA4 into LTB4 and 
LTC4  
There are two forms of human 15-LO, known as 15-LO-1 and 15-LO-2. These 
enzymes share only 40% of similarity in amino acids sequence and might differ in 
their biological functions within cells. 15-LO-1 seems to be present in abundance in 
airway epithelial cells, eosinophils, alveolar macrophages, dendritic cells and 
reticulocytes. It has also been detected in polymorphonuclear leukocytes, alveolar 
macrophages, vascular cells, uterus, the male reproductive system and 
atherosclerotic lesions. In addition to arachidonic acids, 15-LO-1 is also able to act on 
other polyunsaturated fatty acids producing various metabolites (Claesson 2009). 
The 15-LO-1 products depend on the lipid substrates of AA, linoleic acid or 
docosahexanoic acid. Peroxidation of AA substrate produces primarily 15-H(p)ETE 
which is the major product (Claesson 2009), linoleic acid produces 13-H(p)ODE and 
docosahexanoic acid produces 17(S)-H(p)DHA. These lipid compounds play 
important roles in several human tissues. For example, 12(S)-HETE and 15(S)-
HPETE stimulate protein kinase C (PKC) and various cellular adhesion molecules 
(CAMs) which are essential for the monocytes in the vasculature. Additionally, some 
of the products like 13HPODE take part as pro-inflammatory process and act via 
various transcription factors. HETEs products are known to be involved in cell 
proliferation via mitogen-activated protein kinases (MAPKs) (Dobrian et al. 2011). 
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2.4.4.2 15-Lipoxygenase-1 in tumorigenesis 
There is accumulating evidence that LOs and its metabolized products play 
important roles in carcinogenesis including angiogenesis, tumor cell growth, 
invasion, cell survival, metastatic potential and immunomodulation. Contradictory 
results have been demonstrated over the years for 15-LO-1 and its metabolic 
products (Pidgeon et al. 2007). 15-LO-1 and its products were reported to be 
involved in various pathways including vascular, retinal and tumor angiogenesis. 
Studies in human cells lines and several animal models, have revealed that 15-LO-1 
and its products are potentially involved in pro- and anti-angiogenic process 
(Dobrian et al. 2011).   
 
Table 3. Isoforms of five different lipoxygenases (LO) in humans. (From Entrez Gene, 
through the National Center for Biotechnology Information). 5-LO predominantly 
produces leukotrienes (LTs), while 12-LO and 15-LO predominantly produce eicosanoids 
hydroperoxyeicosatetraenoic acid (HPETE) and hydroxyeicosatetraenoic acid (HETE). 
Table modified from Dobrian et al 2011. 
 
Lipoxygenases Abbreviation Alternative  
nomenclature 
Predominant 
enzyme products 
Arachidonate 12-
lipoxygenase 
ALOX12 12S-LO platelet-type 
lipoxygenase 12 
12(S)-HPETE 
12(S)-HETE 
Arachidonate 12-
lipoxygenase 12R 
type 
ALOX12B 12R-LO, epidermis-type 
lipoxygenase 12 
12(R)-HPETE 
12(R)-HETE 
Arachidonate 15-
lipoxygenase 
ALOX15 
 
15-LO-1 
 
15(S)-HPETE, 
15HETE 
 
Arachidonate 15-
lipoxygenase, type 
B 
ALOX15B 15-LO-2; 15-LO-B 15(S)-HPETE, 
15HETE 
 
Arachidonate 
lipoxygenase 3 
ALOXE3 eLO3, epidermis-type 
lipoxygenase 3 
Epoxyalcohols 
(hepoxilins), from 
12(R)-HPETE 
 
15-LO-1 has been proposed to pose anti-cancer properties by increasing rate of 
apoptosis (Shureiqi et al. 2000)  and inhibition of angiogenesis (Harats et al. 2005). 
Harats et al in their study demonstrated the anti-cancer properties of 15-LO-1 in 
transgenic animal models. They used mammary gland and Lewis lung carcinoma 
xenograft animal models to reveal that 15-LO-1 overexpression in endothelial cells 
inhibited tumor progression. The underlying mechanism was explained by 
increasing number of cells undergoing apoptosis and inhibition of angiogenesis 
(Harats et al. 2005). Additionally, studies on human tissues have found that 15-LO-1 
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exhibited anti-cancer properties as the expression was found in normal and benign 
tissues but was absent in carcinomas of bladder, breast, colon or lung (Pidgeon et al. 
2007). In gastric cancer study, the intense expression of 15-LO-1 mediated down-
regulation of PPAR-γ and COX-2 and these inhibited tumor progression (Liu et al. 
2010). However, the pathways have been poorly described so far. Further studies by 
Viita H et al revealed the anti-angiogenic properties of 15-LO-1 in vivo after delivery 
into rabbit skeletal muscles. In their study, 15-LO-1 significantly reduced capillary 
perfusion, vascular permeability, vasodilatation, and increased the capillary number 
induced by VEGF-A and PIGF growth factors (Viita et al. 2008).    
In contrast to those findings, collective data have also shown that 15-LO-1 
expression was highly detected in various cancer cases including prostate cancer, 
lung cancer, breast cancer, melanomas and colonic adenocarcinoma (Kelavkar, 
Glasgow & Eling 2002, Pidgeon et al. 2007) colorectal cancer (Ikawa et al. 1999) as 
compared to controls. The findings pointed out the importance of 15-LO-1 and its 
products in tumor progression and survival. Further evidence has suggested that 15-
LO-1 via its metabolite 15(S)-HETE induced angiogenesis and vessel formation by 
utilizing STAT3-dependent VEGF pathway. Various in vitro and in vivo studies 
indicated that 15-LO may have significant roles in cancer development via 
angiogenesis stimulation (Kundumani-Sridharan et al. 2010, Srivastava et al. 2007).   
Based on the available data, it could be proposed that 15-LO-1 and its metabolites 
may act differently in diverse environments perhaps reflecting the difference of 
tumor location and the isoforms of the products. In fact, their actions in a particular 
stage of cancer development are dissimilar and will require further investigation. 
2.5 ETHICAL CONSIDERATIONS 
2.5.1 Ethical concerns in animal experiments 
Animal experiments play a vital role in providing valuable fundamental information 
on which future medical advances can be built. The development of new medicines 
and treatments collectively contribute to a better life for all members of society. To 
attain such advancements, various types of animal studies are needed. The necessity 
and importance of experimental testing in animals are well known in the scientific 
community. Handling of animals is implemented in an appropriate manner 
according to rules and regulations. Regular check up by the authorized body also 
makes sure handling of animals is always being carried out in responsible ways 
(Festing, Wilkinson 2007).            
In accordance with legislation in Europe, every experimental procedure involving 
animals must confirm to the ethical principles of replacement, reduction, refinement 
and minimization of suffering according to FELASA’s guidelines 
(http://www.felasa.eu/policy-documents/statement-on-the-use-of-live-animals-in-
teaching-and-training/). FELASA also requires all personnel involved in laboratory 
animal care and use, to have the proper education, training and experience when 
performing animal studies. This ensures that all procedures are being properly 
carried out.  
In every experimental setting where animals are the main subjects, efforts for 
replacement, reduction and refinement need to be continuously sought whenever 
possible especially in cases involving animal species closest to human beings as this 
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ensures protection of animals’ well-being and welfare 
(http://ec.europa.eu/european_group_ethics/docs/opinion10_en.pdf).     
In order to obtain ethical approval from the relevant institution, the proposal from 
the researchers has to justify in details what kind of knowledge will be gained 
through the proposed animal experiments. The research procedures also have to 
follow the regulations in the country in which it will be carried out.  
2.5.2 Ethical concerns in gene therapy 
Genetic research has advanced in a dramatic fashion in the last few decades. Now 
gene therapy can realistically be said to be on the verge of curing many serious 
diseases including cancers. Gene therapy aims at modifying genetic defects or 
introducing new genetic materials with which to overcome the illness. Only after 
convincing evidence has accumulated from animal experiments, can researchers 
argue successfully to regulatory agency or institutional review board of a hospital or 
university that they should progress to human studies via safe and adequately 
justified procedures (Steeves, Zariffa & Kramer 2011).  
However, there are many aspects and considerations to be taken into account 
including technical matters and ethical issues. The principles of the research 
approach must cover dignity, freedom, equality, solidarity, citizen’s rights and 
justice. The most important ethical issues regarding gene therapy often originate 
from these questions: the suitability of the cells to be used, safety issues during 
experimental procedures, how safety can best be evaluated in humans, what facts 
are necessary for patients to know so that they can provide informed consent, and 
which diseases are suitable for gene therapy research. For studies carried out in 
Europe, all research activities should reflect the Charter of Fundamental Rights of 
the European Union (http://www.europarl.europa.eu/charter/default_en.htm) and 
take into account the opinions of the European Group on Ethics in Science and New 
Tehcnologies (EGE) (http://ec.europa.eu/european_group_ethics/index_en.htm).     
As gene therapy involves modification of genetic materials, there are concerns 
about the possibility of newly introduced or repaired genes from somatic gene 
therapy gaining access to germ line cells and being inherited to the offspring of the 
patient. However, thorough investigation and careful selection of vectors and target 
cells in gene therapy approach have ensured that these kinds of negative occurrences 
are highly unlikely to happen; there are no reports of this occurring.  
Furthermore, gene therapy has to confront several other ethical considerations. 
These include clinical settings where the potential harms and benefits of the 
treatment have to be weighed, procedural fairness in selection of patients for 
research has to be assured, consent to experimental treatments has to be informed 
and voluntary, and privacy and confidentiality of medical information need to be 
protected (Ferdowsian 2011, Deakin, Alexander & Kerridge 2009).  
Though the legitimate concerns regarding the harms that may be associated with 
gene therapy are often debated, the promise of gene therapy has not diminished. The 
paramount way is to identify the possible implications and to encourage public 
discussion. Today genes technologies embody are still in their infancy, but they can 
provide hope to many patients, and their families and encouragement to scientists 
and physicians who strive to improve the success rate of gene therapy. With 
increasing knowledge of how genes are involved in pathology, one must hope that 
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positive results and novel ideas will make gene therapy to a standard, effective 
treatment in the next few decades. 
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3 Aims of the study  
The general aim of this study was to develop rabbit models which would mimic 
malignant glioma and to evaluate the role of 15-LO-1 and macrophages in the 
treatment and pathogenesis of malignant glioma. 
 
Specifically, the study aimed at: 
 
I) To investigate the potential role of 15-LO-1 as a novel gene therapy 
candidate for malignant gliomas. 
 
II) To characterize the syngeneic BT4C rat malignant glioma model for 
studying the roles of infiltrating macrophages in the pathology of 
malignant gliomas. 
 
III) To utilize the resectable VX-2 rabbit brain tumor model for the evaluation 
of novel therapeutic delivery following brain tumor resection. 
 
IV) To develop a new rabbit malignant glioma model closely mimicking 
human malignant gliomas via lentivirus vector mediated oncogenic 
transformation and intracranial implantation. 
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3 Materials and methods  
The materials and methods used in this study are summarized in the tables (4-8), 
and in Figures 4 and 5. Detailed descriptions are provided in the original 
publications (I and III) and in the manuscripts (II and IV). 
 
 
 
 
 
Figure 4. Schematic representation of the study protocol in publication I. 
 
 
 
 
 
 
 
 
Figure 5. Multiple site injection technique for Adh15-LO-1 gene transfer in publication I. 
Depth is in milimetres from the bregma level. 
 
 
 
 
 
Gene transfer 
day 15-16 
MRI 3 
(day 42) 
MRI 2 
(day 28) 
MRI 1 
(day 14) 
BT4C tumor  
cells inoculation 
Day 0 
2.0 2.0 
2.5 
2.0 
1.5 
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Table 4. A summary of the methods used in this study. 
 
Table 5. A summary of the cell lines used in this study. 
Methods Description Used in 
Viral vector production Adenoviral vector production I, III, IV 
 Lentiviral vector production IV 
   
Cell culture Cell line culture I 
 Primary cell isolation and cell culture IV 
 Viral vector transduction I, IV 
   
In vitro experiments 15-LO-1 activity assay I 
 mRNA isolation and Northern hybridisation I 
 PCR I 
 Lipid peroxidation assay I 
 Caspase-3 enzyme activity assay I 
   
Ex vivo experiments VX-2 tumor cell preparation III 
 Stem cell isolation IV 
   
In vivo experiments Anesthesia, sacrifice, tissue collection I-IV 
 Fixation, embedding, sectioning I-IV 
 Stereotactic injections to rat brain I, II 
 Stereotactic injections to rabbit brain III, IV 
 Tumor cell implantation into rat brain I, II 
 Tumor cell implantation into rabbit brain III 
 Stem cell implantation into rabbit brain IV 
 Tumor resection III 
 Re-passaging of the tumor cells IV 
 Magnetic Resonance Imaging in rat I, II 
 Gene transfer into mice via tail vein I 
   
Immunological methods Immunohistochemistry I-IV 
   
Statistical analysis Kaplan-Mayer log rank test I, III, IV 
 One-way anova I 
   
Animal model Description Origin Used in 
BT4C/BDIX BT4C rat malignant glioma cells 
injected into BDIX rat 
(Sandmair et al. 1999) I, II 
    
VX-2 tumor model VX-2 carcinoma implanted  
into rabbit brain 
(Carson, Anderson & 
Grossman 1982) 
III 
    
Stem cell rabbit 
model 
Stem cells transduced with oncogenes 
and tumor suppressor gene 
implanted into NZW rabbits 
II II 
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Table 6. A summary of the animal models used in this study. 
 
Table 7. A summary of the vectors used in this study. 
 
 
 
 
 
 
 
 
 
 
Animal model Description Origin Used in 
BT4C/BDIX BT4C rat malignant glioma cells 
injected into BDIX rat 
(Sandmair et al. 1999) I, II 
    
VX-2 tumor model VX-2 carcinoma implanted  
into rabbit brain 
(Carson, Anderson & 
Grossman 1982) 
III 
    
Stem cell rabbit 
model 
Stem cells transduced with oncogenes 
and tumor suppressor gene 
implanted into NZW rabbits 
II II 
Vector Description Used in 
Ad-LacZ Recombinant adenovirus containing E.coli  
β-galactosidase under CMV enhancer and 
chicken β-actin promoter 
I, III 
   
Adh15-LO-1 Recombinant adenovirus containing human 
15-LO-1 under CMV promoter 
I 
   
p-Tomo H-RasV12 Recombinant Cre-loxP-controlled lentivirus 
containing human Ras under CMV promoter 
IV 
   
p-Tomo HA-AKT Recombinant Cre-loxP-controlled lentivirus 
containing human AKT under CMV promoter 
IV 
   
AdCre Recombinant adenovirus containing Cre 
recombinase under CMV promoter 
III 
   
Simp53H1 Recombinant Cre-loxP-controlled lentivirus 
containing human p53 siRNA under CMV 
promoter 
I-IV 
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Table 8. A summary of the antibodies used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Description  Origin Used in 
15-LO antibody 
CheY 
Rabbit polyclonal anti-human IHC (Sigal et al. 1990) I 
     
Caspase-3 Rabbit polyclonal anti-human IHC Promega I 
     
CD34 Goat polyclonal anti-rat IHC R&D II 
     
VEGFR-1 Goat anti-rat IHC Santa Cruz II 
     
CD68 Mouse anti-rat IHC AbD Serotec II 
 
CD163 Goat anti-rat IHC Abcam II 
     
CD133 Mouse anti-rat IHC Abcam II 
     
CD31 Mouse anti-human IHC Dako Cytomation III, IV 
     
Ki-67 Mouse anti-human IHC Dako Cytomation III, IV 
     
Β-galactosidase Mouse anti-bacterial IHC Promega III 
     
HA tag Mouse anti-HA-tag IHC Nordic Biosite IV 
     
Flag M2 Mouse anti-human Ms IHC Sigma-Aldrich IV 
     
p53 Mouse anti-human IHC Santa Cruz IV 
     
GFAP Mouse anti-mammalian IHC Abcam IV 
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5 Results  
5.1 POTENTIAL PRO-APOPTOTIC ROLE OF 15-LO-1 GENE THERAPY 
IN MALIGNANT GLIOMA (I) 
Our first study was carried out to investigate the potential roles of 15-LO-1 as a 
novel gene therapy for malignant glioma. In order to clarify its effect, we performed 
in vitro experiments using RAW264.7 macrophages and in vivo experiments in mice 
and syngeneic BT4C rat malignant glioma model.  
 
Figure 6. Tumor volumes in Adh15-LO-1-treated and control animals two weeks (A) and 
four weeks (B) after BT4C cell implantation and gene therapy. C: Kaplan-Meier survival 
analysis of rats after  Adh15-LO-1 gene therapy. After implantation of BT4C cells, rats 
were treated with Adh15-LO-1 (n=12) or followed up as control animals (n=5). The 
median survival of the treated and control groups were 42.5 days and 36.0 days, 
respectively (p=0.001). 
 
Successful transduction of adenovirus carrying human 15-LO-1 virus (Adh15-LO-
1) was shown via the expression of the recombinant protein in RAW264.7 cells at the 
24, 48 and 72 h time points. However, increased activity of the protein was 
significantly detected only after 72 h i.e. this was assessed by measuring the level of 
13-HODE production (25-fold, p<0.001). The result was further confirmed by 
introducing a 15-LO inhibitor PD146176 which very efficiently blocked 15-LO-1 
enzymatic activity (fivefold reduction in Adh15-LO-1-transduced cells vs. Adh15-
LO-1-transduced cells + PD146176).     
We then continued the experiments by injecting the recombinant Adh15-LO-1 
virus into mice via the tail vein. We detected genomic human 15-LO-1 DNA (956 bp 
PCR fragment) only in liver and spleen at three and seven days after injection but 
not in other tissues. Similarly, the highest level of 15-LO-1 mRNA was measured in 
liver and spleen at the same time points but it was also detectable in kidneys, lungs 
and aorta. However, immunohistochemistry only detected 15-LO-1 only in the liver 
and spleen, not in the other organs. The expression of 15-LO-1 was found to be 
uniform in liver and localized in the perifollicular zone, the interface between the 
white pulp and the red pulp.    
Supporting the findings, lipid peroxidation analysis also showed a significant 
increase of MDA and 4-hydroxynonenal (4-HNE) products in the livers of the 
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Adh15-LO-1-transduced mice as compared to controls. The increase was 3.5-fold on 
day three and still 2.0-fold on day 7. Immunohistochemistry staining for the caspase-
3 marker revealed an increased level of positivity in the ADh15-LO-1 virus treated 
mouse livers compared to controls. The cells exhibited the typical morphology of 
cells undergoing apoptosis, i.e. rounded shape, condensation of chromatin and cell 
shrinkage. On the other hand, a significant increase was only detected at day seven 
after transduction with a 32-fold increase in caspase-3 enzymatic activities in the 
liver samples from Adh15-LO-1-transduced mice compared with the control samples 
from AdlacZ-transduced mice.       
To study its therapeutic effect, rat malignant glioma model was used to test the 
therapeutic effects of Adh15-LO-1 gene therapy. The tumor growth was monitored 
with MRI. Two weeks after the introduction of Adh15-LO-1, MRI data showed no 
significant difference in the tumor size between the groups, although there was a 
clear tendency for smaller tumors in the Adh15-LO-1 group (38.49±5.164 mm3 vs. 
52.71±5.201 mm3). The images indicated that the gene therapy showed an effect but 
did not fully suppress the tumor growth. At four weeks, 50% of the Adh15-LO-1 
treated animals were still alive, while none of the control animals survived up to this 
timepoint. The median survival time in Adh15-LO-1-treated animals was 42.5 days 
and 36.0 days in control animals. Observations of animal well-being revealed no 
significant toxicity associated with the treatment. Clinical chemistry analysis (red 
blood cells, white blood cells, haemoglobin, platelets, alanine aminotransferase, 
aspartate aminotransferase, creatinine, bilirubin and urea) did not show any changes 
after the gene therapy treatment. Immunohistochemistry was carried out to 
determine the expression level of 15-LO-1 and the apoptosis related protein, caspase-
3. A positive reaction for 15-LO-1 was detected in the transduction area but no 
significant increase of apoptotic cells was observed (p=0.1).  
5.2 INFILTRATING MACROPHAGES IN BT4C MALIGNANT GLIOMA 
MODEL (II) 
In this study, the BT4C rat malignant glioma was used as a malignancy model to 
investigate the interaction between the tumor microenvironment and tumor cells. 
Several immunostainings were carried out including CD34 VEGFR-1, CD68, CD163 
and CD133 as well as H&E. 
The BT4C tumor cells were found to be infiltrating into the surrounding healthy 
brain tissue, with numerous microsatellite lesions at the tumor edges as revealed in 
the H&E stainings. Interestingly, immunohistochemistry staining with CD133 
marker revealed that the infiltrating tumor cells and cells distant from the tumor 
were positive for the stem cells marker, which often correlates with a poor prognosis 
in many cancer cases. CD133 positivity has also been associated with a higher 
invasive and aggressive nature of many cancer cells.      
Furthermore, BT4C rat malignant glioma also demonstrated high angiogenic 
characteristics as shown by CD34 staining. Immunohistochemistry staining revealed 
a high density of the vasculature throughout the tumor. In addition, we also 
detected vasculogenic mimicry in some positive vessels where the vessels were 
missing endothelial cells. It seemed that vasculogenic mimicry was found more often 
in the center compared to edge of the tumor. Immunostaining for VEGFR-2 revealed 
high protein expression in the glioma cells and also within some blood vessels.    
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To assess presence of M2 macrophage subtype within the tumor, immunostaining 
was performed using the CD68 marker. It was observed that up to 35% of the tumor 
was positive for CD68 similar to the usual amount found in human malignant 
gliomas. Moreover, CD68 positivity was also detected in some clusters distant from 
the tumor and in the endothelium in some blood vessels. To confirm these findings, 
it was decided to carry out staining for CD163, another marker for M2 macrophages. 
Similarly to the CD68 observation, a high expression of CD163 was detected 
throughout the tumor as well as in clusters distant from the tumor area. However, 
no blood vessels with CD163 positive endothelium were found.  
As the staining results for CD68 and CD163 supported each other, it was decided 
to differentiate M1 and M2 macrophages by CD68/VEGFR-1 double staining. 
Theoretically, the M1 subtype of macrophages does not express VEGFR-1. The 
results revealed that only a subset of CD68 positive cells were expressing VEGFR-1, 
appearing as individual clusters, which were mainly concentrated at the infiltrative 
edges, whereas the centers of the malignant gliomas were mainly positive for CD68. 
No CD68/VEGFR-1 positive cells could be detected distant from the tumor.  
5.3 CHARACTERIZATION OF VX-2 RABBIT BRAIN TUMOR MODEL 
(III) 
The aim of this study was to establish a novel therapeutic delivery method using the 
VX-2 rabbit brain tumor model. Twenty-two out of 24 animals which developed 
tumors were divided into non-resected and resected groups. Nine animals were 
subjected to tumor resection and followed up for the survival. The median survival 
for the non-resected group was 23 days and for the resected group 37 days, i.e. there 
was a 60.8% prolongation in survival of the resected animals compared to their non-
resected counterparts. Kaplan-Mayer analysis revealed a highly significant 
difference between the non-resected and resected groups (P< .001).  
The volumes of resected tumors ranged from 30-300 mm3, the largest tumors being 
about 7.0 mm in diameter. Similar to the situation in human malignant glioma, very 
large rabbit VX-2 brain tumors that grow partially into the contralateral hemisphere 
can be considered as inoperable since the sagital vein possess through the area 
which would need to be removed. VX-2 brain tumors reached the appropriate size 
for tumor resection around 2-3 weeks after tumor implantation. The tumors grew to 
respectably relevant sizes in a relatively short time as the time from inoculation to 
resection was on average only 18 days. During the tumor removal operation, a larger 
opening was necessary to allow optimal access to the tumor area. Typically, a 
number of exceptionally large blood vessels were seen around and leading into the 
tumors, evidence of strong tumor angiogenesis. Before the tumors could be resected, 
all surrounding blood vessels had to be coagulated to avoid serious hemorrhaging 
during the procedure. The tumor was then easily removed using microsurgical 
techniques. In all of the operated animals, the tumor was successfully resected with 
no operation related mortality. Generally, it was possible to avoid penetration to the 
lateral ventricle. However, in a few animals the tumor was growing through the 
lateral ventricle wall and in these cases, penetration into the lateral ventricle could 
not be avoided.   
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Figure 7. VX-2 tumor growth after tumor implantation (A). MRI data was acquired twice 
a week to measure the tumor volumes. The Kaplan-Meyer log rank analysis verified a 
highly significant difference in survival of non-resected and resected group animals (P< 
.001) (B).   
 
 
Histologic analysis of VX-2 brain tumors revealed that the tumors were 
characterized by large a central necrotic area which was suggestive of the presence 
of a hypoxic environment similarly to that found in high grade brain tumors in 
humans. In addition, peritumoral edema was detected. VX-2 tumor cells 
demonstrated highly aggressive and invasive growth. However, unlike the situation 
in malignant glioma where single tumor cells are scattered into the surrounding 
normal brain tissue, the VX-2 cells typically invade the surrounding brain as small 
clusters. The tumor borders of VX-2 tumors were ill-defined as they were 
intermingled with normal brain cells. The invasive nature of the VX-2 brain tumors 
likely contributed to the limited long term therapeutic effect of the tumor resection, 
similarly to clinical experience in patients suffering from malignant glioma and brain 
metastases, where the infiltrating tumor cells lead to a recurrent disease within the 
site of the previously resected tumor.  
The CD31 immunostainings confirmed that VX-2 tumors were highly angiogenic. 
Statistical analysis revealed that the number of blood vessels in the VX-2 tumors was 
significantly higher than in the normal brain (P< .001). In addition, the diameter of 
the vessels was significantly larger within the tumors compared to vessels in the 
normal brain (P= .004). The mean capillary size for VX-2 tumor area was 955 μm2 
which was nearly five times larger than those in the normal brain area (200 μm2) 
(Figure 4A). Staining for proliferation marker Ki-67 demonstrated that VX-2 tumors 
were highly proliferative with a number of positively stained proliferating cells seen 
in the tumor area (Figure 4B). 
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Figure 8. Comparison of capillary number (A) and capillary diameter (μm2) (B) within the 
VX-2 tumor area and normal brain area (control). Statistical analysis revealed a highly 
significant difference between the number of capillaries (A, p< 0.001) and the diameter 
of the capillaries (B, p= 0.004) in both groups.  
 
The efficiency of adenovirus vector mediated gene transfer was investigated with 
commonly used local stereotactic injections into the walls of the resection cavity. Lac 
Z positivity was detected in immunostaining in all animals at least at 2 injection sites 
with <5% transduction efficiency. LacZ expression was detected in both tumor cells 
and in cells of the brain parenchyma around the injection sites. The majority of the 
transduced cells were normal CNS cells. 
5.4 DEVELOPMENT OF NOVEL RABBIT BRAIN TUMOR MODEL VIA 
GENETIC MODULATION (IV) 
In an attempt to develop a novel malignant glioma model in rabbits, lentiviruses 
carrying constitutively active AKT and H-Ras oncogenes, and p53 siRNA were 
administered into newborn rabbit neural stem cells (NSCs) and these were 
intracranially implanted into rabbit brain to initiate tumor formation. MRI data 
showed tumor growth after 48 days of NSCs implantation with a success rate of 
10%. MRI follow-up revealed the slow growth of the tumor up to day 141, when the 
animal was eventually sacrificed. 
Histological examination of the tumor demonstrated it similarities to the tumor 
histopathology of a benign Grade II ganglioglioma. The ganglion and glial cells 
made up the tumor which was characterized as a large, rounded tumor with nuclear 
atypia and multinucleated cells. The presence of microcalcification within the tumor 
area also was one of the important features normally found in gangliogliomas in 
humans. The tumor borders were ill defined with tumor cells scattered within the 
surrounding brain tissue. Peritumoral edema was also detected.  
Specific immunostaining detected the expression of constitutively active AKT and 
H-Ras transgenes in the tumor tissue. GFAP protein was also strongly expressed 
throughout the tumor, similarly to the situation in the many ganglioglioma subtypes 
(Karremann et al. 2009, Zhang et al. 2008). However, it was not possible to 
conclusively demonstrate that the activity of p53 had been blocked by the 
introduction of the p53 siRNA as the control healthy brain also showed a very low 
expression of the protein.  
The tumor consisted a dense network of small branching capillaries and highly 
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proliferative tumor cells as shown by the staining with CD31 and Ki-67 markers, 
respectively. Unlike in most low grade gangliogliomas, numerous proliferation 
figures were found in this tumor, which may indicate progression to an anaplastic 
stage of the tumor (Rogojan, Olinici 2008). Usually less than 5% of tumor cells are 
expressing Ki-67 in grade II gangliogliomas (Rousseau et al. 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. MRI data was acquired once every two weeks in order to measure the tumor 
volumes. Tumor growth was detected for the first time at 48 days after implantation. 
Tumor growth was monitored until day 141 when the animal was sacrificed. 
In order to determine localization of AKT and RAS proteins, double staining for 
both markers was carried out. The results illustrated the heterogeneous cell 
populations which expressed either AKT or H-Ras or both in the same cells. Another 
double staining was carried out for PAS-CD31 to investigate the presence of tumor 
cells around the vessels within the tumor area. Interestingly, PAS positivity was 
found lining nearly all of the CD31 positive channels. CD31-positivity was identified 
on the luminal surface of the vessels whereas a PAS-positive pattern was found in 
the vessel wall of the intratumoral vessels, suggesting that there was vascular co-
option mostly in the peritumoral area. Likewise, the occurrence of the vascular co-
option in human astrocytoma has also been reported (Yue, Chen 2005). However, no 
vasculogenic mimicry was observed. 
The reproducibility of the tumor was also tested via subcutaneous re-implantation 
into immunodeficient SCID mice. H&E staining demonstrated the presence of mixed 
cell population of reactive ganglion and glial cells in the tumor tissue, thus 
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demonstrating that this tumor was reproducible. Some oligodendroglia cells were 
also detected; these were characterized by pale nuclei and clear perinuclear area due 
to inflammation. Additionally, reactive astrocytes showed dark nuclei and atypia.  
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6 Discussion  
6.1 PROLONGED SURVIVAL BY 15-LIPOXYGENASE-1 IN RAT 
MALIGNANT GLIOMA MODEL (I) 
Gene therapy has become one of the most promising therapeutic approaches to treat 
many devastating cancers including GBM. Extensive research in the field has yielded 
improvements in gene therapy techniques and drug development. In an attempt to 
evaluate the potential antitumorigenic roles of 15-LO-1 in GBM, the Adh15-LO-1 
gene was introduced into the tumor cavity of BT4C rat malignant glioma model.  
15-LO-1 is a lipid-peroxidizing enzyme which function is to oxygenate 
unsaturated fatty acids in cells. It has been claimed to take part in various 
pathological functions including inflammation, atherogenesis and carcinogenesis. 
15-LO-1 also possesses antitumorigenic effects by inducing apoptosis (Shureiqi et al. 
2000) and inhibiting angiogenesis (Harats et al. 2005). However, contradicting results 
of 15-LO-1 functions have also been reported by some researchers who observed 
pro-apoptotic roles for this enzyme (Kelavkar, Glasgow & Eling 2002, Pidgeon et al. 
2007). The expression level of 15-LO-1 is high in several types of cancer including 
prostate cancer, lung cancer, breast cancer, melanomas and colonic adenocarcinoma. 
The conflicting data of the roles of 15-LO-1 may be influenced by the production of 
its diverse metabolites in various cancer tissues where different types and ratios of 
the metabolites can catalyze a wide variety of bioactivities in the microenvironments 
around the cancer tissue. The complexity of 15-LO-1 and its metabolites in cancers 
will certainly require further studies and evaluation.       
This study showed that the use of Adh15-LO-1 gene therapy for GBM induced 
apoptosis in an effective manner, which may offer a new therapeutic approach in the 
battle against cancer. Apoptotic activity in the tumor was revealed via the detection 
of lipid peroxidation products and the caspase-3 level.   
To our knowledge, this is the first study investigating the roles of 15-LO-1 in the 
GBM animal model. 15-LO-1 treatment achieved a significant prolongation of the 
survival time compared to the control group. Moreover, slower tumor growth was 
also detected in the treatment groups as compared to control although the result was 
not significant.      
Previously it has been shown that 15-LO-1 also possesses strong antiangiogenic 
activity via down-regulation of the VEGFR-2 pathway (Viita et al. 2008). Therefore, it 
is likely that the antitumorigenic effects of 15-LO-1 involve both proapoptotic actions 
and antiangiogenic properties of the enzyme. The current results indicate that 15-
LO-1 could represent a good candidate for combination therapy of GBM. 
6.2 BT4C MALIGNANT GLIOMA MODEL TO STUDY INVOLVEMENT 
OF TUMOR ASSOCIATED MACROPHAGES (II) 
Inflammation is known to play an important role in the development of various 
cancers. Inflammatory cells, such as macrophages, show a high tendency to infiltrate 
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MG tumors and have recently been identified as supporting tumor growth and 
metastasis (Joyce, Pollard 2009, De Visser, Eichten & Coussens 2006). Macrophages 
also affect immune surveillance and tumor responses to therapy. Currently, there are 
two subtypes of macrophages that have been described. The M1 subtype is 
classically activated while M2 is alternatively activated in tumor environment.  
It has been stated that macrophages in tumor microenvironment engage in a 
dynamic crosstalk with cancer cells, even though the mechanism is not yet clear. In 
an attempt to understand the interaction between macrophages and tumor cells in 
vivo, the BT4C rat malignant glioma model was used in this study.    
BT4C rat malignant glioma model displays several characteristics of human 
malignant gliomas, including a high level of vascularization and the appearance of 
microsattelitic lesions distant from the tumors. Glioma cells invade into healthy 
surroundings as individual cells or groups of cells which often correlates with poor 
prognosis in glioma patients (Claes, Idema & Wesseling 2007). Moreover, the 
infiltrating cells at the tumor edges were detected as positive for the CD133 marker, 
suggesting that these cells exhibited the potential to transdifferentiate into 
endothelial cells or more appropriately to acquire endothelial-like properties, 
contributing to angiogenesis in malignant gliomas.    
High expression levels of VEGFR-2 was detected in these malignant glioma 
samples, which is believed to involve the VEGF-A/VEGFR-2 pathway of 
angiogenesis. The vascular endothelial growth factor (VEGF) family and its 
receptors seem to be a central signaling pathway in glioma angiogenesis, but there 
are many other important factors which act angiogenically, e.g. basic fibroblast 
growth factor (bFGF), platelet-derived growth factor (PDGF), hepatocyte growth 
factor/scatter factor (SF) and the angiopoietins (Ang). 
Additionally, high expression of VEGFR-2 has also been shown to correlate with 
high grade of gliomas (Puputti et al. 2006). This finding also supports the concept 
that the VEGF signaling pathway was enhancing growth and viability of tumor cells. 
Recently, the presence of VEGFR-2 on the surface of tumor associated macrophages 
has been implicated as an important chemotactic receptor essential for VEGF-
stimulated migration of tumor associated macrophages into tumors (Dineen et al. 
2008). 
In our malignant glioma tissue, there was extensive infiltration of cells positive for 
the macrophage marker, CD68, surrounding the infiltrating tumor cells. One could 
speculate that macrophages had been attracted to the tumor cells and their crosstalk 
had enhanced the invasive nature of these cells to penetrate into the surrounding 
tissue. Additionally, the presence of macrophages lining around blood vessels was 
also detected by CD68 staining. A similar finding has also been reported previously 
(Murdoch et al. 2008).   
From these findings, it seems that the BT4C malignant glioma model is an 
appropriate model for studying the tumor microenvironment and its influence on 
tumor invasion and growth. The model displays many similarities with the clinical 
situation in human patients including inflammation and macrophage infiltration.  
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6.3 RABBIT ANIMAL MODEL TO STUDY MALIGNANT GLIOMAS (III, 
IV) 
Tumor resection is a standard therapeutic intervention for brain tumors. Currently, 
surgery is the optimal achieving means for a palliative treatment, relieving the 
typical symptoms of brain tumors, however survival benefits are not to be 
underestimated. There is a general agreement among clinicians that the more 
complete the tumor removal, the better the prognosis. Patchell et al. reported that 
surgical debulking of the tumor would be effective in the treatment of single brain 
metastases, since it was able to prolong survival by 32 weeks (Patchell et al. 1990). At 
present, surgery followed by whole brain radiotherapy is recommended as the 
treatment of choice for newly diagnosed single brain metastases (Kalkanis et al. 
2010). Moreover, surgical resection can improve the efficacy of adjuvant therapies. 
Therefore, utilizing an animal model that would make it possible to assess the 
efficacy of innovative treatment approaches in combination with gross surgical 
resection would be a major advance.  
Gene therapy, oncolytic virotherapy and immunotherapy are examples of 
promising therapeutic strategies to be applied against brain malignancies. However, 
studies in rodent models have shown that the local administration route is superior 
for optimal efficiency and safety in these therapeutic modalities. The lack of easily 
available resectable brain tumor model may be one of the reasons why these 
promising treatment possibilities have often failed as they are transferred from 
rodent models to human patients, i.e. the preclinical testing and actual clinical 
treatment strategies differ dramatically. The efficient evaluation of novel therapies 
requires reproducible and accurate animal models that not only recapitulate key 
features of the disease but also are able to reproduce the treatment regimes which 
will be applied in the clinical environments. Particularly surgical debulking is 
appreciated as a critical intervention. Nevertheless, the rodent models widely 
utilized in basic research are unable to predict the effects of resection on the therapy. 
Surgical intervention not only affects the application route of further treatments, but 
it is believed that it may change the efficacy of adjuvant therapies (Ng, Wan & Too 
2007, Stewart 2002, Barker et al. 2001). Importantly, after debulking of aggressive 
primary or metastatic brain tumor, invasive cells will frequently give rise to a 
recurrent tumor, which arises adjacent to the resection margin leading to a fatal 
outcome.  
For example, local delivery of gene therapy vectors into the wound bed would 
enable an appropriate evaluation of safety and efficacy in an environment where 
most of the surrounding cells are normal brain cells mixed with a relatively small 
proportion of malignant cells. This may provide important information for treatment 
which is targeting a bystander effect as in cytotoxic or anti-angiogenic therapy, or 
immunostimulatory gene therapy with cytokine genes, to be able to provide 
adequate therapeutic outcome without harming normal brain cells.  
6.3.1 VX-2 RABBIT BRAIN TUMOR MODEL (III) 
VX-2 tumors were implanted into immunocompetent rabbits. This was considered as 
an important aspect the model should closely recapitulate the immunological 
conditions that exist in brain tumor patients. Moreover, since these animals have an 
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intact immune system, they are suitable for testing therapies that enhance the host 
immune responses against cancer. The tumor growth rates were shown to be 
predictable and reproducible. The aggressive growth of VX-2 tumors resembles the 
rapid progression of human malignant gliomas and brain metastases. Additionally, 
it was shown that MRI can be employed for in vivo monitoring of tumor growth and 
its recurrence. Tumor resection surgery has been proven to be relatively easy to 
perform and therefore experimentally applicable in an ordinary laboratory. The 
histological examination revealed that the VX-2 tumors exhibited the key features of 
aggressive malignant brain tumors in humans, such as strong angiogenesis, a high 
rate of proliferation, central necrosis, peritumoral edema and angiogenesis and 
tumor cell invasion into the surrounding tissue. VX-2 tumors possess the invasive 
characteristics similar to those encountered in human high grade brain malignancies 
as they are highly infiltrative and demonstrate a diffuse spread of malignant cells 
into non-neoplastic parenchyma. Importantly, the infiltration of surrounding healthy 
tissue complicates total surgical debulking in VX-2 tumors similar to the case 
patients with malignant brain tumors, where the tumor typically recurs at the 
previous site from a residual pool of invasive cells. The scarcity of models that reflect 
these kinds of invasive patterns in the brain is a significant problem. For example, 
even in many of the commonly used rodent models that are mimicking highly 
invasive brain malignancies, tumors tend to grow in the brain as a single bulk mass 
(Claes et al. 2008). The rabbit VX-2 brain tumor model allows for resection and local 
application of therapeutic agents into the walls of the resection cavity. Thus, this 
model can be useful for evaluating local application routes for drugs against 
metastatic brain tumors and high grade gliomas. Importantly, VX-2 could be utilized 
not only for testing initial tumor treatment delivery methods, but also those that 
could possibly be used to combact disease recurrence. 
Previous studies have shown that utilization of dogs as a large animal model for 
brain tumor is both attractive and advantageous. The GBM tumor in the dog model 
also shares several characteristics with human tumors. However, the spontaneous 
brain tumor in dog occurs at low frequency with a variable tumor rate, and this 
makes the recruitment difficult and not suitable for routine testing (Candolfi et al. 
2007). 
Gene therapy is a promising approach for the treatment of primary and metastatic 
malignant brain tumors. Still, a major problem has been a lack of efficacy upon 
systemic administration. A major obstacle preventing the development of more 
efficient local administration methods has been the lack of an easily accessible 
animal model that would permit tumor resection prior to administration of gene 
therapy, and in that way mimic  the clinical protocols. Gene therapy experiments on 
rodent models are most commonly performed using direct stereotactic intratumoral 
injections (Immonen et al. 2004, Mizuno, Ryuke & Yoshida 2002). However, the 
clinical delivery of gene therapy can vary from clinic to clinic. For example, in the 
Cerepro study (Ark Therapeutics Group plc), which evaluated HSV-TK/ganciclovir 
cytotoxic gene therapy, the patients underwent craniotomy for radical resection 
using routine neuronavigation. Viral vectors were administered directly into the 
wound bed after tumor resection and the patients received multiple injections, 
depending on the size of the tumor cavity (Immonen et al. 2004). Here the efficiency 
of adenovirus vector mediated gene transfer was examined with stereotactic 
injections into the resection cavity walls achieving successful marker gene 
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expression. One could predict the resectable VX-2 rabbit brain tumor model could 
facilitate development of innovative local gene delivery approaches that would 
bring closer the days of efficient gene transfer in the clinical setting. It could also be 
used to study the efficacies of therapies and delivery methods targeting to reach 
tumor satellite cells. 
6.3.2 ONCOGENIC TRANSFORMATION INDUCES RABBIT BRAIN 
TUMOR (IV) 
Numerous efforts have been made to develop genetically engineered animal models 
using mice. To our knowledge, currently there is no report of rabbit animal models 
for studying brain tumors. In this study, we implemented the concept of using AKT 
and H-Ras oncogenes in combination with p53 siRNA to develop a brain tumor 
model in rabbits.  
Previously, Marumoto et al. has successfully developed GBM tumors in GFAP-Cre 
transgenic mice by introducing Cre-LoxP controlled lentivirus vectors 
administrering AKT and H-Ras into the subventricular zone or hippocampus brain 
regions where a high number of stem cells are located. They discovered an increase 
in tumorigenicity by using p53 heterozygous mice in both regions (Marumoto et al. 
2009). 
Human GBM is a heterogenous tumor composed from tumor cells and small 
portion of CSC, also known as GIC, which have a high tumorigenic potential. CSC 
are resistant to chemotherapy and radiotherapy and are therefore thought to be 
responsible for tumor progression and recurrence after conventional glioblastoma 
therapy. It is believed that clones of CSCs in the GBM tumor mass develop via 
genetic and epigenetic changes in neural stem/progenitor cells or the differentiated 
cells such as astrocytes after a series of mutations or epigenetic reprogramming. This 
small population of cells possesses the characteristics necessary to survive, duplicate, 
or spread within this microenvironment.  
CSCs also display a higher tumorigenicity potential than non-stem tumor cells 
when implanted into rodents. Since they possess the ability to differentiate into 
astrocytes, oligodendrocytes and neurons, the numbers of CSCs have correlated with 
development of aggressive behavior of human GBM (Huang et al. 2010). 
In this study, newborn rabbit NSCs were isolated and cultured ex vivo before 
being transduced with Cre-LoxP controlled lentivirus vectors encoding for AKT and 
H-Ras oncogenes, adenovirus vector carrying Cre recombinase gene and lentivirus 
vector with the p53 siRNA expression cassette. Consequently, the cells were 
subcortically implanted into brain cortex of NZW rabbits into a location that would 
allow surgical resection of tumors (Ahmad et al. 2011). Interestingly, tumor 
development occurred which later was identified as grade II ganglioglioma.  
Ganglioglioma is a rare type of central nervous system tumor which is mostly 
detected in young patients (<30 years old). The tumor arises from ganglion cells and 
is characterized by its biphasic histological arcitechture involving transformed 
neuronal and glial components (Blumcke, Wiestler 2002). The benign tumor is 
typically well differentiated and slowly growing (Luyken et al. 2004, Im et al. 2002). 
The low tumorigenicity in this present study could be influenced by the age of the 
NSCs and an efficiency problem of having all of the transgenes in a single cell. To 
our knowledge, the molecular pathogenesis of ganglioglioma which has no atypical 
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or malignant features is poorly known. Based on the present staining data, it seems 
unlikely that AKT and Ras oncogenes play a vital role in the development of the 
tumor. A previous report has described the activated role of AKT in ganglioglioma, 
but no evidence was found with regard to Ras (Boer et al. 2010). However, it was not 
possible to verify the blocked expression of p53 tumor suppressor gene by siRNA. In 
the previous study by Marumoto et al with AKT and H-Ras transgene induced 
tumors, the proportion of Ki-67 positive tumor cells increased from about 1%  to 5.5 % 
when p53 heterozygous mice were used instead of normally p53 expressing mice 
(Marumoto et al. 2009). In the present study, a high number of cells expressing Ki-67 
was detected, indicating that there was tumor cell proliferation, perhaps suggesting 
a reduced activity or inactivation of p53. 
The malignant transformation of ganglioglioma into high grade glioma has been 
described previously with an association with a p53 mutation/inactivation (Pandita 
et al. 2007, Kim et al. 2003). As seen in this present study, the detection of high Ki-67 
expression in rabbit ganglioglioma represents a marker for the malignant 
transformation into anaplastic ganglioglioma.    
In addition to the age factor, it is possible that several other factors contribute to 
the low tumorigenicity seen in this study: An inadequate number of NSCs in the 
implanted region i.e. cortex rather than a more favorable areas such as hippocampus 
or the sub ventricular area, may be one factor in unsuccessful malignant tumor 
formation. The suitability of the microenvironment including the supply of growth 
factors in the cortex area is likely to be unfavorable as compared to other regions 
which are rich with NSCs. Furthermore, the properties of NSCs may have changed 
during the ex vivo culturing leading to reduced tumorigenicity. Nevertheless, this 
study has provided valuable information regarding the use of lentivirus vectors and 
genetic manipulations for development of larger animal model, such as the rabbit. 
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7 Conclusion  
In conjunction with present results and their interpretation, the following 
conclusions are made: 
 
I) 15-LO-1 demonstrates a great potential as a novel gene therapy candidate 
as it sachieveds a significant improvement in survival in a rat malignant 
glioma model. Furthermore, 15-LO-1 demonstrated a clear tendency to be 
able to delay tumor growth.  
 
II) It is evident that BT4C rat malignant glioma tumor is highly infiltrated 
with macrophages and inflammation is also one of the main features in the 
pathogenesis of tumor formation. This model has displayed suitable 
properties to allow it to be utilized as a platform to study the 
microenvironment and its influence on tumor growth and invasion.   
 
III) The VX-2 rabbit brain tumor model has proven to be reproducible and 
technically relatively easy to use. It mimics the key features of growth and 
the pathology of malignant brain tumors in humans. Importantly, it 
provides the possibility to test locally delivered promising therapeutics in 
combination with tumor debulking surgical procedures that are crucial 
components of current clinical treatment protocols. Thereby, it can 
complement studies carried out in rodent models and facilitate successful 
translation to the clinic. 
 
IV) A construct of lentiviral vectors carrying constitutively active AKT and 
Ras oncogenes and mouse p53 siRNA was successfully shown to induce 
tumor growth in rabbit brain resembling type II ganglioglioma in humans.   
 
To summarize, these present results show that 15-LO-1 holds great potential as a 
promising new gene therapy candidate to decrease tumor growth and to improve 
survival in the BT4C rat animal model. Additionally, the BT4C rat malignant glioma 
model is demonstrated to be suitable for investigating the interplay between 
macrophages and tumor cells within the tumor microenvironment. Moreover, it is 
believed that the rabbit VX-2 model is a suitable model for testing promising 
therapeutic drugs/agents following tumor resection. This is the first report of the 
possibility of inducing rabbit brain tumor via manipulation of oncogenic pathways 
in combination with p53 siRNA. 
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Glioblastoma multiforme is the most 
devastating form of glial tumors. 
To ensure successful gene therapy 
application in clinics, accurate in 
vivo model is clearly needed. This 
thesis aimed to evaluate the role of 
15-lipoxygenase-1 and macrophages 
in the treatment and pathogenesis 
of malignant glioma and to develop 
rabbit models which would allow for 
tumor debulking surgery. The results 
demonstrated that 15-lipoxygenase-1 
significantly improved animal 
survival. Moreover, rabbit models 
highlighted the possibility for 
surgical debulking procedures 
followed by gene therapy delivery.
